Movatterモバイル変換


[0]ホーム

URL:


SG10201912895PA - Chiral control - Google Patents

Chiral control

Info

Publication number
SG10201912895PA
SG10201912895PASG10201912895PASG10201912895PASG10201912895PASG 10201912895P ASG10201912895P ASG 10201912895PASG 10201912895P ASG10201912895P ASG 10201912895PASG 10201912895P ASG10201912895P ASG 10201912895PASG 10201912895P ASG10201912895P ASG 10201912895PA
Authority
SG
Singapore
Prior art keywords
chiral control
chiral
control
Prior art date
Application number
SG10201912895PA
Inventor
David Charles Donnell Butler
Naoki Iwamoto
Meena
Nenad Svrzikapa
Gregory L Verdine
Ivan Zlatev
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences LtdfiledCriticalWave Life Sciences Ltd
Publication of SG10201912895PApublicationCriticalpatent/SG10201912895PA/en

Links

Classifications

Landscapes

SG10201912895PA2012-07-132013-07-12Chiral controlSG10201912895PA (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US201261671655P2012-07-132012-07-13
US201261671656P2012-07-132012-07-13
US201261671722P2012-07-142012-07-14
US201261671724P2012-07-142012-07-14

Publications (1)

Publication NumberPublication Date
SG10201912895PAtrue SG10201912895PA (en)2020-02-27

Family

ID=49916709

Family Applications (3)

Application NumberTitlePriority DateFiling Date
SG10201912895PASG10201912895PA (en)2012-07-132013-07-12Chiral control
SG11201500232UASG11201500232UA (en)2012-07-132013-07-12Chiral control
SG10201700283WASG10201700283WA (en)2012-07-132013-07-12Chiral control

Family Applications After (2)

Application NumberTitlePriority DateFiling Date
SG11201500232UASG11201500232UA (en)2012-07-132013-07-12Chiral control
SG10201700283WASG10201700283WA (en)2012-07-132013-07-12Chiral control

Country Status (16)

CountryLink
US (4)US9982257B2 (en)
EP (2)EP2872147B1 (en)
JP (4)JP6453212B2 (en)
KR (4)KR20240148947A (en)
CN (2)CN104661664B (en)
AU (5)AU2013289880B2 (en)
CA (1)CA2878945A1 (en)
CL (1)CL2015000092A1 (en)
DK (1)DK2872147T3 (en)
ES (1)ES2940887T3 (en)
IL (1)IL236621B (en)
MX (1)MX2015000577A (en)
PL (1)PL2872147T3 (en)
RU (1)RU2015104762A (en)
SG (3)SG10201912895PA (en)
WO (1)WO2014012081A2 (en)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN102282155B (en)2008-12-022017-06-09日本波涛生命科学公司The synthetic method of the nucleic acid of phosphorus atoms modification
KR101885383B1 (en)2009-07-062018-08-03웨이브 라이프 사이언시스 리미티드Novel nucleic acid prodrugs and methods of use thereof
WO2012039448A1 (en)2010-09-242012-03-29株式会社キラルジェンAsymmetric auxiliary group
CA2817960C (en)2010-11-172020-06-09Isis Pharmaceuticals, Inc.Modulation of alpha synuclein expression
US9605019B2 (en)2011-07-192017-03-28Wave Life Sciences Ltd.Methods for the synthesis of functionalized nucleic acids
AU2013202595B2 (en)2012-03-302016-04-21Biogen Ma Inc.Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
KR101835401B1 (en)2012-07-132018-03-08신 니뽄 바이오메디칼 라보라토리즈, 엘티디.Chiral nucleic acid adjuvant
SG10201912895PA (en)2012-07-132020-02-27Wave Life Sciences LtdChiral control
AU2013288048A1 (en)2012-07-132015-01-22Wave Life Sciences Ltd.Asymmetric auxiliary group
MX2015012621A (en)2013-03-142016-05-31Ionis Pharmaceuticals IncCompositions and methods for modulating tau expression.
TWI702046B (en)2013-07-192020-08-21美商Ionis製藥公司Compositions for modulating tau expression
EP3095459A4 (en)2014-01-152017-08-23Shin Nippon Biomedical Laboratories, Ltd.Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (en)2014-01-152017-03-23株式会社新日本科学 Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
WO2015108047A1 (en)2014-01-152015-07-23株式会社新日本科学Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JP6382344B2 (en)*2014-01-162018-08-29ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. Chiral design
WO2015125845A1 (en)*2014-02-202015-08-27塩野義製薬株式会社Phosphate site modification of nucleic acid containing nitrogen-containing non-aromatic heterocycle
US10214743B2 (en)2014-03-042019-02-26Hirofumi YamamotoColorectal cancer drug, and method for predicting prognosis of colorectal cancer patient
JP7026440B2 (en)2014-05-282022-02-28ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Hybrid tRNA / premiRNA molecules and usage
GB201410693D0 (en)2014-06-162014-07-30Univ SouthamptonSplicing modulation
RU2708237C2 (en)2014-08-222019-12-05Общество с ограниченной ответственностью "НооГен"Modified oligonucleotides and method for production thereof
CA2963288A1 (en)2014-10-032016-04-07Cold Spring Harbor LaboratoryTargeted augmentation of nuclear gene output
US20180112217A1 (en)*2014-11-192018-04-26Roche Innovation Center Copenhagen A/SStereospecific Phosphorothioate LNA
WO2016096938A1 (en)*2014-12-162016-06-23Roche Innovation Center Copenhagen A/SChiral toxicity screening method
DK3234134T3 (en)2014-12-172020-07-27Proqr Therapeutics Ii Bv TARGETED RNA EDITING
MA43072A (en)*2015-07-222018-05-30Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
US10533175B2 (en)2015-09-252020-01-14Ionis Pharmaceuticals, Inc.Compositions and methods for modulating Ataxin 3 expression
AU2016334232B2 (en)*2015-10-092022-05-26Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
KR102422625B1 (en)2015-10-092022-07-20유니버시티 오브 사우스앰톤 Regulation of gene expression and screening of deregulated protein expression
US11096956B2 (en)2015-12-142021-08-24Stoke Therapeutics, Inc.Antisense oligomers and uses thereof
EP3933041B1 (en)2015-12-142024-01-31Cold Spring Harbor LaboratoryAntisense oligomers for treatment of autosomal dominant retardation
WO2017131208A1 (en)*2016-01-282017-08-03東レ株式会社Pharmaceutical composition for treating and/or preventing cancer
EP3430019A4 (en)*2016-03-132019-10-30Wave Life Sciences Ltd. COMPOSITIONS AND METHODS FOR SYNTHESIZING PHOSPHORAMIDITY AND OLIGONUCLEOTIDES
US11267843B2 (en)2016-03-182022-03-08Roche Innovation Center Copenhagen A/SStereodefining L-monomers
MA45471A (en)2016-04-012019-02-06Avidity Biosciences Llc PHOSPHATIDYLINOSITOL-3-KINASE NUCLEIC ACIDS AND THEIR USES
MA45469A (en)2016-04-012019-02-06Avidity Biosciences Llc BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
MA45349A (en)2016-04-012019-02-06Avidity Biosciences Llc EGFR NUCLEIC ACIDS AND THEIR USES
MA45328A (en)2016-04-012019-02-06Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
MA45470A (en)2016-04-012019-02-06Avidity Biosciences Llc KRAS NUCLEIC ACIDS AND THEIR USES
JP7033547B2 (en)2016-04-182022-03-10サレプタ セラピューティクス, インコーポレイテッド Antisense oligomers for treating diseases associated with the acidic alpha-glucosidase gene and methods using them
NZ747685A (en)2016-04-292023-05-26Sarepta Therapeutics IncOligonucleotide analogues targeting human lmna
MA45270A (en)*2016-05-042017-11-09Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
US11261209B2 (en)*2016-05-122022-03-01Roche Innovation Center Copenhagen A/SEnhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
WO2017198775A1 (en)*2016-05-182017-11-23Eth ZurichStereoselective synthesis of phosphorothioate oligoribonucleotides
MA45188A (en)*2016-06-032019-04-10Wave Life Sciences Ltd OLIGONUCLEOTIDES, ASSOCIATED COMPOSITIONS AND METHODS
MA45496A (en)2016-06-172019-04-24Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
CA3024944A1 (en)2016-06-222017-12-28Proqr Therapeutics Ii B.V.Single-stranded rna-editing oligonucleotides
SG11201810143PA (en)2016-06-302019-01-30Sarepta Therapeutics IncExon skipping oligomers for muscular dystrophy
WO2018035380A1 (en)2016-08-172018-02-22Solstice Biologics, Ltd.Polynucleotide constructs
US10941402B2 (en)2016-09-012021-03-09Proqr Therapeutics Ii B.V.Chemically modified single-stranded RNA-editing oligonucleotides
JOP20190065A1 (en)2016-09-292019-03-28Ionis Pharmaceuticals IncCompounds and methods for reducing tau expression
JOP20190104A1 (en)*2016-11-102019-05-07Ionis Pharmaceuticals IncCompounds and methods for reducing atxn3 expression
CN110088113A (en)*2016-11-232019-08-02波涛生命科学有限公司Composition and method for phosphoramidite and oligonucleotide synthesis
AU2017368050A1 (en)2016-11-292019-06-20Puretech Lyt, Inc.Exosomes for delivery of therapeutic agents
KR102552428B1 (en)2016-12-192023-07-06사렙타 쎄러퓨틱스 인코퍼레이티드 Exon skipping oligomeric conjugates for dyskinesia
RS63705B1 (en)2016-12-192022-11-30Sarepta Therapeutics Inc OLIGOMER CONJUGATES FOR EXON SKIPPING FOR MUSCULAR DYSTROPHY
MX2019006879A (en)2016-12-192019-08-01Sarepta Therapeutics Inc EXON OMISSION OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY.
KR20240172236A (en)2017-01-062024-12-09어비디티 바이오사이언시스 인크.Nucleic acid-polypeptide compositions and methods of inducing exon skipping
US11274300B2 (en)2017-01-192022-03-15Proqr Therapeutics Ii B.V.Oligonucleotide complexes for use in RNA editing
WO2018181428A1 (en)2017-03-292018-10-04塩野義製薬株式会社Complex of nucleic acid medicine and multibranched lipid
CN110475784B (en)*2017-03-292024-07-16罗氏创新中心哥本哈根有限公司Orthogonal protecting groups for preparing stereotactic phosphorothioate oligonucleotides
CN111164091B (en)*2017-06-022025-01-07波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
JP2020522510A (en)*2017-06-022020-07-30ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. Oligonucleotide composition and method of using the same
US11597927B2 (en)2017-06-022023-03-07Wave Life Sciences Ltd.Oligonucleotide compositions and methods of use thereof
CN111051281A (en)*2017-06-212020-04-21波涛生命科学有限公司Compounds, compositions and methods for synthesis
WO2019002237A1 (en)*2017-06-282019-01-03Roche Innovation Center Copenhagen A/SMultiple coupling & oxidation method
WO2019006455A1 (en)2017-06-302019-01-03Solstice Biologics, Ltd.Chiral phosphoramidite auxiliaries and methods of their use
GB201711809D0 (en)2017-07-212017-09-06Governors Of The Univ Of AlbertaAntisense oligonucleotide
US20200362337A1 (en)*2017-08-082020-11-19Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
EP4303321A3 (en)2017-08-252024-07-24Stoke Therapeutics, Inc.Antisense oligomers for treatment of conditions and diseases
KR20250123934A (en)*2017-09-182025-08-18웨이브 라이프 사이언시스 리미티드Technologies for oligonucleotide preparation
EA201991450A1 (en)2017-09-222019-12-30Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
US20200254002A1 (en)2017-09-282020-08-13Sarepta Therapeutics, Inc.Combination therapies for treating muscular dystrophy
EP3687577A1 (en)2017-09-282020-08-05Sarepta Therapeutics, Inc.Combination therapies for treating muscular dystrophy
US20200248178A1 (en)2017-09-282020-08-06Sarepta Therapeutics, Inc.Combination therapies for treating muscular dystrophy
KR102822647B1 (en)2017-10-042025-06-19어비디티 바이오사이언시스 인크. Nucleic acid-polypeptide composition and use thereof
WO2019075357A1 (en)2017-10-122019-04-18Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
TW202424191A (en)2017-10-162024-06-16瑞士商赫孚孟拉羅股份公司Nucleic acid molecule for reduction of papd5 and papd7 mrna for treating hepatitis b infection
WO2019079637A2 (en)2017-10-182019-04-25Sarepta Therapeutics, Inc.Antisense oligomer compounds
TWI809004B (en)*2017-11-092023-07-21美商Ionis製藥公司Compounds and methods for reducing snca expression
WO2019092280A1 (en)*2017-11-132019-05-16Silence Therapeutics GmbhNucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
SI3717646T1 (en)2017-12-012025-08-29The Texas A&M University SystemAngelman syndrome antisense treatment
SG11202005022YA (en)2017-12-062020-06-29Avidity Biosciences IncCompositions and methods of treating muscle atrophy and myotonic dystrophy
WO2019126651A1 (en)2017-12-212019-06-27Alnylam Pharmaceuticals, Inc.Chirally-enriched double-stranded rna agents
CN108186564B (en)*2018-01-032020-06-02上海市肿瘤研究所 A kind of tumor microenvironment responsive gene nanomicelle and its preparation method and application
US12203068B2 (en)2018-02-042025-01-21The Texas A&M University SystemHeterochiral nucleic acid strand-displacement systems and methods
WO2019175126A1 (en)*2018-03-142019-09-19F. Hoffmann-La Roche AgLna-dicarboxylic acid derivatives and process for their preparation
IL277889B2 (en)*2018-04-122025-01-01Wave Life Sciences LtdOligonucleotide compositions and methods of use thereof
BR112020022512A2 (en)2018-05-042021-05-04Stoke Therapeutics, Inc. methods and compositions for treating cholesteryl ester storage disease
KR20210018267A (en)2018-05-072021-02-17알닐람 파마슈티칼스 인코포레이티드 Extrahepatic delivery
CN112189053B (en)2018-05-092024-05-14Ionis制药公司Compounds and methods for reducing ATXN3 expression
WO2019217784A1 (en)2018-05-112019-11-14Wave Life Sciences Ltd.Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en)2018-05-182018-07-11Proqr Therapeutics Ii BvStereospecific Linkages in RNA Editing Oligonucleotides
US10758629B2 (en)2018-05-292020-09-01Sarepta Therapeutics, Inc.Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en)2018-06-132022-06-22Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
PE20210346A1 (en)2018-07-032021-02-25Hoffmann La Roche OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TAU
TW202449155A (en)2018-07-272024-12-16美商薩羅塔治療公司Exon skipping oligomers for muscular dystrophy
WO2020118246A1 (en)*2018-12-062020-06-11Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
EP3894558A1 (en)2018-12-132021-10-20Sarepta Therapeutics, Inc.Exon skipping oligomer conjugates for muscular dystrophy
IL319265A (en)2018-12-212025-04-01Avidity Biosciences IncAnti-transferrin receptor antibodies and uses thereof
CN109837326B (en)*2019-01-172022-07-05嘉兴学院Biological target molecule detection method based on multivalent capture and output signal amplification
JP7424363B2 (en)*2019-02-272024-01-30日産化学株式会社 Resin compositions, resin films and liquid crystal display elements
SG11202110045PA (en)*2019-03-202021-10-28Wave Life Sciences LtdTechnologies useful for oligonucleotide preparation
CA3134683A1 (en)*2019-03-262020-10-01Rutgers, The State University Of New JerseyCompositions and methods for treating neurodegenerative disorders
EP3955966A1 (en)2019-04-182022-02-23Sarepta Therapeutics, Inc.Compositions for treating muscular dystrophy
EP3972983A4 (en)*2019-05-172023-05-24Ionis Pharmaceuticals, Inc.Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphate diester linkages
CN110346493B (en)*2019-05-232021-01-05中国人民解放军军事科学院军事医学研究院 Method for detecting midkine antisense oligonucleotide content in rhesus monkey plasma
CN114375297A (en)2019-06-062022-04-19艾维迪提生物科学公司UNA imides and uses thereof
AU2020289464A1 (en)2019-06-062022-01-20Avidity Biosciences, Inc.Nucleic acid-polypeptide compositions and uses thereof
WO2021154941A1 (en)*2020-01-312021-08-05Alnylam Pharmaceuticals, Inc.Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
CA3172111A1 (en)2020-03-192021-09-23Barbora MALECOVACompositions and methods of treating facioscapulohumeral muscular dystrophy
MX2022011880A (en)2020-03-272022-10-20Avidity Biosciences Inc COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY.
AU2021270720A1 (en)2020-05-112022-12-08Stoke Therapeutics, Inc.OPA1 antisense oligomers for treatment of conditions and diseases
MX2022014606A (en)2020-05-222023-03-08Wave Life Sciences LtdDouble stranded oligonucleotide compositions and methods relating thereto.
CN112063608B (en)*2020-08-272022-06-17浙江工业大学 A fatty acid photodecarboxylase mutant and its application in the synthesis of L-glufosinate
WO2023043953A1 (en)2021-09-162023-03-23Avidity Biosciences, Inc.Compositions and methods of treating facioscapulohumeral muscular dystrophy
CA3233242A1 (en)2021-09-302023-04-06Sarepta Therapeutics, Inc.Antisense oligonucleotides having one or more abasic units
CN114230498B (en)*2021-12-302023-11-17湖北华世通生物医药科技有限公司Preparation method of beta- (dimethylamino) ethyl p-toluenesulfonate hydrochloride
CN115181736B (en)*2022-01-072023-05-30中国科学院海洋研究所Protease PCK capable of being combined with lipopolysaccharide and preparation and application thereof
US20250154504A1 (en)2022-02-142025-05-15Proqr Therapeutics Ii B.V.Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
US12071621B2 (en)2022-04-052024-08-27Avidity Biosciences, Inc.Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2024013360A1 (en)2022-07-152024-01-18Proqr Therapeutics Ii B.V.Chemically modified oligonucleotides for adar-mediated rna editing
JP2025524566A (en)2022-07-152025-07-30プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ Oligonucleotides for ADAR-mediated RNA editing and uses thereof
WO2024064237A2 (en)2022-09-212024-03-28Sarepta Therapeutics, Inc.Dmd antisense oligonucleotide-mediated exon skipping efficiency
GB202215614D0 (en)2022-10-212022-12-07Proqr Therapeutics Ii BvHeteroduplex rna editing oligonucleotide complexes
WO2024097310A2 (en)*2022-11-012024-05-10Impilo Therapeutics, Inc.Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes
EP4623084A1 (en)2022-11-242025-10-01ProQR Therapeutics II B.V.Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en)2022-12-012023-01-18Proqr Therapeutics Ii BvAntisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
EP4630553A1 (en)2022-12-092025-10-15ProQR Therapeutics II B.V.Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en)2023-01-202023-03-08Proqr Therapeutics Ii BvDelivery of oligonucleotides
WO2024175550A1 (en)2023-02-202024-08-29Proqr Therapeutics Ii B.V.Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
KR102767906B1 (en)*2023-03-062025-02-19주식회사 아이씨바이오Method for producing plant-derived nucleic acid using an eco-friendly extraction method
WO2024206175A1 (en)2023-03-242024-10-03Proqr Therapeutics Ii B.V.Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en)2023-03-242023-05-10Proqr Therapeutics Ii BvChemically modified antisense oligonucleotides for use in RNA editing
WO2024200472A1 (en)2023-03-272024-10-03Proqr Therapeutics Ii B.V.Antisense oligonucleotides for the treatment of liver disease
US20250066776A1 (en)2023-04-272025-02-27Sarepta Therapeutics, Inc.Antisense oligomers for treatment of chronic kidney disease
AR132964A1 (en)2023-06-162025-08-13Proqr Therapeutics Ii Bv ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2025007063A1 (en)2023-06-302025-01-02Avidity Biosciences, Inc.Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
WO2025015335A1 (en)2023-07-132025-01-16Korro Bio, Inc.Rna-editing oligonucleotides and uses thereof
WO2025051946A1 (en)2023-09-072025-03-13Proqr Therapeutics Ii B.V.Antisense oligonucleotides for the treatment of metabolic disorders
WO2025064469A1 (en)2023-09-182025-03-27Omega Therapeutics, Inc.Methods for assessing dosage for epigenetic modifying agents
WO2025085810A2 (en)2023-10-182025-04-24Sarepta Therapeutics, Inc.Antisense oligomers for treatment of centronuclear myopathies
WO2025096809A1 (en)2023-10-312025-05-08Korro Bio, Inc.Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en)2023-11-162025-05-22Proqr Therapeutics Ii B.V.Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en)2023-12-122025-06-19Korro Bio, Inc.Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en)2023-12-202025-06-26Proqr Therapeutics Ii B.V.Antisense oligonucleotides for the treatment of huntington's disease

Family Cites Families (650)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US513030A (en)1894-01-16Machine for waxing or coating paper
US2878264A (en)1959-03-17Substituted amino alcohols
DE133885C (en)
CH372667A (en)1957-09-261963-10-31Robins Co Inc A H Process for the preparation of 3-aryl-3-pyrrolidinols
US3135766A (en)1961-10-031964-06-02Mead Johnson & Co3-substituted-3-pyrrolidinols
US3484473A (en)1967-05-121969-12-16Buckman Labor IncMethylene bisesters of thiolsulfonic acids
DE1934150A1 (en)1968-07-101970-01-15Pennwalt Corp New 1-alkanoyloxy-1,2,4,5-tetrahydro-3H, 3-benzazepine
US3687808A (en)1969-08-141972-08-29Univ Leland Stanford JuniorSynthetic polynucleotides
US3745162A (en)1970-08-311973-07-10Robins Co Inc A H1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en)1973-02-241976-09-08Beecham Group LtdDiphenylpropylamines
US4022791A (en)1975-06-031977-05-10Pfizer Inc.2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en)1975-08-091978-03-22Beecham Group LtdIsoquinoline-derived aminoethers
BR7807288A (en)1977-11-081979-06-12Genentech Inc POLYNUCLEOTIDE SYNTHESIS PROCESS
DD133885B1 (en)1978-01-041981-02-25Hans Lehmann AGENTS FOR THE CONTROL OF PHYTOPATHOGENIC BACTERIA AND MUSHROOMS
US4458066A (en)1980-02-291984-07-03University Patents, Inc.Process for preparing polynucleotides
US5132418A (en)1980-02-291992-07-21University Patents, Inc.Process for preparing polynucleotides
US4500707A (en)1980-02-291985-02-19University Patents, Inc.Nucleosides useful in the preparation of polynucleotides
US4415732A (en)1981-03-271983-11-15University Patents, Inc.Phosphoramidite compounds and processes
US4973679A (en)1981-03-271990-11-27University Patents, Inc.Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en)1981-03-271987-05-26University Patents, Inc.Phosphoramidite nucleoside compounds
US4542142A (en)1982-11-221985-09-17Roussel UclafInsecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
USRE34069E (en)1983-08-181992-09-15Biosyntech GmbhProcess for the preparation of oligonucleotides
DE3329892A1 (en)1983-08-181985-03-07Köster, Hubert, Prof. Dr., 2000 Hamburg METHOD FOR PRODUCING OLIGONUCLEOTIDES
US5118800A (en)1983-12-201992-06-02California Institute Of TechnologyOligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en)1984-07-111997-07-01Temple University-Of The Commonwealth System Of PennsylvaniaCholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (en)1984-07-191989-02-17Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5367066A (en)1984-10-161994-11-22Chiron CorporationOligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (en)1985-01-081987-04-03Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
FR2576898B1 (en)1985-02-011988-01-08Lafon Labor 3-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES, METHOD OF PREPARATION AND THERAPEUTIC USE
US4659774A (en)1985-11-011987-04-21American Hoechst CorporationSupport for solid-phase oligonucleotide synthesis
US4735949A (en)1986-02-181988-04-05Warner-Lambert CompanyDisubstituted-7-pyrrolidinonaphthyridine antibacterial agents
US4840956A (en)1986-02-181989-06-20Warner-Lambert CompanyNovel disubstituted-7-pyrrolidinoquinoline antibacterial agents
IL83663A0 (en)1986-10-271988-01-31Robins Co Inc A HPreparation of 3-pyrrolidinols
EP0366685B1 (en)1987-06-241994-10-19Howard Florey Institute Of Experimental Physiology And MedicineNucleoside derivatives
US5200553A (en)1987-07-301993-04-06Kupat Holim Health Insurance Institution Of The General Federation Of LaborBiologically active carboxylic acid esters
US4923901A (en)1987-09-041990-05-08Millipore CorporationMembranes with bound oligonucleotides and peptides
US5175273A (en)1988-07-011992-12-29Genentech, Inc.Nucleic acid intercalating agents
US5047524A (en)1988-12-211991-09-10Applied Biosystems, Inc.Automated system for polynucleotide synthesis and purification
US5262530A (en)1988-12-211993-11-16Applied Biosystems, Inc.Automated system for polynucleotide synthesis and purification
JP2794461B2 (en)1989-08-171998-09-03有機合成薬品工業株式会社 Phosphoramidite compounds and solid-phase synthesis of oligoribonucleotides using the same
US5141813A (en)1989-08-281992-08-25Clontech Laboratories, Inc.Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en)1989-08-291992-07-28Monsanto CompanyImproved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en)1989-12-041991-06-05Christine L. BrakelModified nucleotide compounds
US5130302A (en)1989-12-201992-07-14Boron Bilogicals, Inc.Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
EP0507863A4 (en)1989-12-281993-07-07Virginia Commonwealth UniversitySigma receptor ligands and the use thereof
US5587470A (en)1990-01-111996-12-24Isis Pharmaceuticals, Inc.3-deazapurines
US5620963A (en)1991-10-151997-04-15Isis Pharmaceuticals, Inc.Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
KR927003044A (en)1990-01-111992-12-17크리스토퍼 케이. 미라벨리 Composition and method for detecting and regulating RNA activity and gene expression
US6339066B1 (en)1990-01-112002-01-15Isis Pharmaceuticals, Inc.Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5212295A (en)1990-01-111993-05-18Isis PharmaceuticalsMonomers for preparation of oligonucleotides having chiral phosphorus linkages
US5681941A (en)1990-01-111997-10-28Isis Pharmaceuticals, Inc.Substituted purines and oligonucleotide cross-linking
US5587361A (en)1991-10-151996-12-24Isis Pharmaceuticals, Inc.Oligonucleotides having phosphorothioate linkages of high chiral purity
US5914396A (en)1990-01-111999-06-22Isis Pharmaceuticals, Inc.2'-O-modified nucleosides and phosphoramidites
US5635488A (en)1991-10-151997-06-03Isis Pharmaceuticals, Inc.Compounds having phosphorodithioate linkages of high chiral purity
US5646265A (en)1990-01-111997-07-08Isis Pharmceuticals, Inc.Process for the preparation of 2'-O-alkyl purine phosphoramidites
US7101993B1 (en)1990-01-112006-09-05Isis Pharmaceuticals, Inc.Oligonucleotides containing 2′-O-modified purines
US5852188A (en)1990-01-111998-12-22Isis Pharmaceuticals, Inc.Oligonucleotides having chiral phosphorus linkages
US5457191A (en)1990-01-111995-10-10Isis Pharmaceuticals, Inc.3-deazapurines
US5459255A (en)1990-01-111995-10-17Isis Pharmaceuticals, Inc.N-2 substituted purines
US5506212A (en)1990-01-111996-04-09Isis Pharmaceuticals, Inc.Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5292875A (en)1990-04-201994-03-08Lynx Therapeutics, Inc.Method of synthesizing sulfurized oligonucleotide analogs
US5151510A (en)1990-04-201992-09-29Applied Biosystems, Inc.Method of synethesizing sulfurized oligonucleotide analogs
FI925210A0 (en)1990-05-231992-11-17Isis Pharmaceuticals Inc COMPOSITION OF FOERFARANDEN FOR MODULATION OF AV RNA MOLECULAR ACTIVITY GENOM MODIFICATION OF AV CAP STRUCTURES AND RNA MOLECULAR 5 'AENDA
US5705337A (en)1990-06-111998-01-06Nexstar Pharmaceuticals, Inc.Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5726017A (en)1990-06-111998-03-10Nexstar Pharmaceuticals, Inc.High affinity HIV-1 gag nucleic acid ligands
US5580737A (en)1990-06-111996-12-03Nexstar Pharmaceuticals, Inc.High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5846713A (en)1990-06-111998-12-08Nexstar Pharmaceuticals, Inc.High affinity HKGF nucleic acid ligands and inhibitors
US5567588A (en)1990-06-111996-10-22University Research CorporationSystematic evolution of ligands by exponential enrichment: Solution SELEX
US5668264A (en)1990-06-111997-09-16Nexstar Pharmaceuticals, Inc.High affinity PDGF nucleic acid ligands
US5861254A (en)1997-01-311999-01-19Nexstar Pharmaceuticals, Inc.Flow cell SELEX
US5496938A (en)1990-06-111996-03-05Nexstar Pharmaceuticals, Inc.Nucleic acid ligands to HIV-RT and HIV-1 rev
EP0533838B1 (en)1990-06-111997-12-03NeXstar Pharmaceuticals, Inc.Nucleic acid ligands
US5587468A (en)1990-06-111996-12-24University Research CorporationHigh affinity nucleic acid ligands to HIV integrase
US6331394B1 (en)1991-06-102001-12-18Gilead Sciences, Inc.Nucleic acid ligands to integrins
US6001577A (en)1998-06-081999-12-14Nexstar Pharmaceuticals, Inc.Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6232071B1 (en)1990-06-112001-05-15Gilead Sciences, Inc.Tenascin-C nucleic acid ligands
US5543293A (en)1990-06-111996-08-06Nexstar Pharmaceuticals, Inc.DNA ligands of thrombin
US5503978A (en)1990-06-111996-04-02University Research CorporationMethod for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5780228A (en)1990-06-111998-07-14Nexstar Pharmaceuticals, Inc.High affinity nucleic acid ligands to lectins
US5683867A (en)1990-06-111997-11-04Nexstar Pharmaceuticals, Inc.Systematic evolution of ligands by exponential enrichment: blended SELEX
US5527894A (en)1990-06-111996-06-18Nexstar Pharmacueticals, Inc.Ligands of HIV-1 tat protein
US5869641A (en)1990-06-111999-02-09Nexstar Pharmaceuticals, Inc.High affinity nucleic acid ligands of CD4
US5654151A (en)1990-06-111997-08-05Nexstar Pharmaceuticals, Inc.High affinity HIV Nucleocapsid nucleic acid ligands
US6261774B1 (en)1990-06-112001-07-17Gilead Sciences, Inc.Truncation selex method
US5637459A (en)1990-06-111997-06-10Nexstar Pharmaceuticals, Inc.Systematic evolution of ligands by exponential enrichment: chimeric selex
US5610289A (en)1990-07-271997-03-11Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogues
EP0544824B1 (en)1990-07-271997-06-11Isis Pharmaceuticals, Inc.Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5432272A (en)1990-10-091995-07-11Benner; Steven A.Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en)1991-03-061996-04-30Polish Academy Of SciencesSolid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en)1991-12-242006-03-21Isis Pharmaceuticals, Inc.Gapped oligonucleotides
US6414112B1 (en)1991-05-242002-07-02Ole BuchardtPeptide nucleic acids having 2,6-diaminopurine nucleobases
AU659649B2 (en)1991-06-101995-05-25Lucky LimitedHepatitis C diagnostics and vaccines
US5646267A (en)1991-08-051997-07-08Polish Academy Of SciencesMethod of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en)1991-08-051994-10-25Polish Academy Of SciencesChalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US7119184B2 (en)1991-08-122006-10-10Isis Pharmaceuticals, Inc.Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en)1999-05-032002-04-09Isis Pharmaceuticals, Inc.Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5654284A (en)1991-10-151997-08-05Isis Pharmaceuticals, Inc.Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5607923A (en)1991-10-151997-03-04Isis Pharmaceuticals, Inc.Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
CA2121144C (en)1991-10-152001-07-31Phillip Dan CookOligonucleotides having chiral phosphorus linkages
US5661134A (en)1991-10-151997-08-26Isis Pharmaceuticals, Inc.Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5576302A (en)1991-10-151996-11-19Isis Pharmaceuticals, Inc.Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5599797A (en)1991-10-151997-02-04Isis Pharmaceuticals, Inc.Oligonucleotides having phosphorothioate linkages of high chiral purity
EP0538194B1 (en)1991-10-171997-06-04Novartis AGBicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5594121A (en)1991-11-071997-01-14Gilead Sciences, Inc.Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en)1991-11-261996-01-16Gilead Sciences, Inc.Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en)1991-11-262001-05-22Isis Pharmaceuticals, Inc.Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en)1991-12-131994-10-25Isis PharmaceuticalsCyclobutyl oligonucleotide surrogates
AU669353B2 (en)1991-12-241996-06-06Isis Pharmaceuticals, Inc.Gapped 2' modified oligonucleotides
WO1993023569A1 (en)1992-05-111993-11-25Ribozyme Pharmaceuticals, Inc.Method and reagent for inhibiting viral replication
WO2002081494A1 (en)2001-03-262002-10-17Sirna Therapeutics, Inc.Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
GB9213601D0 (en)1992-06-261992-08-12Mastico Robert AProtein based delivery system
EP0654077A4 (en)1992-07-171996-03-13Ribozyme Pharm IncMethod and reagent for treatment of animal diseases.
US7067497B2 (en)1992-09-292006-06-27Isis Pharmaceuticals, Inc.Modulation of telomere length by oligonucleotides having a G-core sequence
FI953541L (en)1993-01-251995-08-31Hybridon Inc Oligonucleotide alkylphosphonates and alkylphosphonothioates
JPH08508490A (en)1993-03-311996-09-10スターリング ウィンスロップ インコーポレイティド Novel 5'-substituted nucleosides and oligomers obtained therefrom
US5955591A (en)1993-05-121999-09-21Imbach; Jean-LouisPhosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)1993-05-242000-01-18Chemgenes CorporationOligonucleotide phosphate esters
DE69412704T2 (en)1993-06-101999-02-04Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo Injection mold
US5502177A (en)1993-09-171996-03-26Gilead Sciences, Inc.Pyrimidine derivatives for labeled binding partners
US5643989A (en)1993-10-291997-07-01Azdel, Inc.Fiber reinforced functionalized polyolefin composites
DE69435100D1 (en)1993-10-292008-06-26Brigham & Womens Hospital THERAPEUTIC USE OF CIS ELEMENT CASE IN VIVO
WO1998003542A1 (en)1996-07-241998-01-29Buchardt, DortePeptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5457187A (en)1993-12-081995-10-10Board Of Regents University Of NebraskaOligonucleotides containing 5-fluorouracil
DE4435728A1 (en)1994-01-191995-07-20Boehringer Mannheim Gmbh Biotin silane compounds and binding matrix containing these compounds
AU1838295A (en)1994-02-101995-08-29Nexagen, Inc.High-affinity ligands of basic fibroblast growth factor and thrombin
US6117679A (en)1994-02-172000-09-12Maxygen, Inc.Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
JP3553958B2 (en)1994-02-222004-08-11ノボザイムス アクティーゼルスカブ Method for producing variant of lipolytic enzyme
US5596091A (en)1994-03-181997-01-21The Regents Of The University Of CaliforniaAntisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
EP0759073A1 (en)1994-05-111997-02-26Novo Nordisk A/SAN ENZYME WITH ENDO-1,3(4)-$g(b)-GLUCANASE ACTIVITY
US5525711A (en)1994-05-181996-06-11The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesPteridine nucleotide analogs as fluorescent DNA probes
US6239116B1 (en)1994-07-152001-05-29University Of Iowa Research FoundationImmunostimulatory nucleic acid molecules
US6207646B1 (en)1994-07-152001-03-27University Of Iowa Research FoundationImmunostimulatory nucleic acid molecules
CA2560114A1 (en)1994-07-151996-02-01The University Of Iowa Research FoundationImmunomodulatory oligonucleotides
ATE202569T1 (en)1994-09-072001-07-15Hybridon Inc PRODRUG OLIGONUCLEOTIDES
US5681940A (en)1994-11-021997-10-28Icn PharmaceuticalsSugar modified nucleosides and oligonucleotides
WO1996019572A1 (en)1994-12-221996-06-27Hybridon, Inc.Synthesis of stereospecific oligonucleotide phosphorothioates
GB9501465D0 (en)1995-01-251995-03-15King S College LondonNucleoside phosphorothioate derivatives,synthesis and use thereof
AU5301996A (en)1995-03-061996-09-23Nexstar Pharmaceuticals, Inc.High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
JPH10512894A (en)1995-03-061998-12-08アイシス・ファーマシューティカルス・インコーポレーテッド Improved method for the synthesis of 2'-O-substituted pyrimidines and their oligomeric compounds
US6166197A (en)1995-03-062000-12-26Isis Pharmaceuticals, Inc.Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0739983B1 (en)1995-04-272009-12-30Takara Bio Inc.Gene encoding lacto-n-biosidase
WO1996035782A1 (en)1995-05-111996-11-14Applied Research SystemsIl-6 activity inhibitor
AU5871196A (en)1995-05-231996-12-24Hybridon, Inc.Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
AU5869696A (en)1995-05-231996-12-11Hybridon, Inc.Novel synthons for stereoselective oligonucleotide synthesis
JPH10510433A (en)1995-06-061998-10-13アイシス・ファーマシューティカルス・インコーポレーテッド Oligonucleotides with high chiral purity phosphorothioate linkages
US6111095A (en)1995-06-072000-08-29Merck & Co., Inc.Capped synthetic RNA, analogs, and aptamers
US6699843B2 (en)1995-06-072004-03-02Gilead Sciences, Inc.Method for treatment of tumors using nucleic acid ligands to PDGF
US5932450A (en)1995-06-071999-08-03Gen-Probe IncorporatedEnzymatic synthesis of oligonucleotides using digestible templates
US5795765A (en)1995-06-291998-08-18Takara Shuzo Co., Ltd.Gene encoding endoglycoceramidase
EP0759470B1 (en)1995-06-292006-10-25Takara Bio Inc.Gene encoding endoglycoceramidase activator
US6017700A (en)*1995-08-042000-01-25Bayer CorporationCationic oligonucleotides, and related methods of synthesis and use
US5936080A (en)1996-05-241999-08-10Genta IncorporatedCompositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en)1995-09-051997-03-13Michigan State UniversityPROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5734041A (en)1995-10-201998-03-31Mcgill UniversityPreparation of chiral phosphorothioate oligomers
US6476216B1 (en)1995-10-202002-11-05Mcgill UniversityPreparation of phosphorothioate oligomers
US6160109A (en)1995-10-202000-12-12Isis Pharmaceuticals, Inc.Preparation of phosphorothioate and boranophosphate oligomers
US5856085A (en)1995-12-011999-01-05The Penn State Research FoundationCompositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
US7018793B1 (en)1995-12-072006-03-28Diversa CorporationCombinatorial screening of mixed populations of organisms
JP2000505646A (en)1996-02-012000-05-16ネクスター・ファーマシューティカルズ・インコーポレーテッド High affinity nucleic acid ligands for complement system proteins
US6214805B1 (en)1996-02-152001-04-10The United States Of America As Represented By The Department Of Health And Human ServicesRNase L activators and antisense oligonucleotides effective to treat RSV infections
WO1997029757A1 (en)1996-02-151997-08-21National Institutes Of HealthRnase l activators and antisense oligonucleotides effective to treat rsv infections
GB9604669D0 (en)1996-03-051996-05-01Ciba Geigy AgChemical compounds
US5824669A (en)1996-03-221998-10-20Nitromed, Inc.Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
AU3025597A (en)1996-05-101997-12-05Novo Nordisk A/SMethod of providing novel dna sequences
US5856465A (en)1996-05-241999-01-05Polska Akademia Nauk Centrum Badan Molekularnych I MakromolekularnychCompositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en)1996-06-061999-04-27Isis Pharmaceuticals, Inc.Oligoribonucleotides for cleaving RNA
DE19622783A1 (en)1996-06-071997-12-11Hoechst Ag Isolation of the biosynthetic genes for pseudo-oligosaccharides from Streptomyces glaucescens GLA.O and their use
DE69736667T2 (en)1996-07-162007-09-06Gen-Probe Inc., San Diego PROCESS FOR THE DETECTION AND AMPLIFICATION OF NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES WITH INCREASED TARGET MELT TEMPERATURE (TM)
WO1998007734A1 (en)1996-08-211998-02-26Hybridon, Inc.Oligonucleotide prodrugs
WO1998008809A1 (en)1996-08-301998-03-05Hybridon, Inc.Novel sulfur transfer reagents for oligonucleotide synthesis
US6056973A (en)1996-10-112000-05-02Sequus Pharmaceuticals, Inc.Therapeutic liposome composition and method of preparation
US6051698A (en)1997-06-062000-04-18Janjic; NebojsaVascular endothelial growth factor (VEGF) nucleic acid ligand complexes
HU0000769A (en)1996-12-272000-07-28G-rich oligo aptamers and methods of modulating an immune response
US6172209B1 (en)1997-02-142001-01-09Isis Pharmaceuticals Inc.Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en)1997-02-142003-10-28Isis Pharmaceuticals, Inc.Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en)1997-03-072002-04-09President And Fellows Of Harvard CollegeDNA glycosylase inhibitors, and uses related thereto
US6015887A (en)1997-04-112000-01-18Isis Pharmaceuticals, Inc.Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en)1997-04-212002-10-22The Cleveland Clinic FoundationRNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (en)1997-04-252002-11-29PanMethod of obtaining p-chiral analoques of nucleotides
AU745309B2 (en)1997-05-282002-03-21Peter E. NielsenConjugated peptide nucleic acids having enhanced cellular uptake
US6589940B1 (en)1997-06-062003-07-08Dynavax Technologies CorporationImmunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999005160A2 (en)1997-07-251999-02-04Hybridon, Inc.Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6767739B2 (en)2001-07-302004-07-27Isis Pharmaceuticals Inc.Antisense modulation of microsomal triglyceride transfer protein expression
GB9717158D0 (en)1997-08-131997-10-22King S College LondonSolution synthesis of oligonucleotides and their phosphorothioate analogues
US6383808B1 (en)2000-09-112002-05-07Isis Pharmaceuticals, Inc.Antisense inhibition of clusterin expression
US6750344B1 (en)1997-09-052004-06-15Isis Pharmaceuticals, Inc.Amine compounds and combinatorial libraries comprising same
DE19741715A1 (en)1997-09-221999-03-25Hoechst AgNew pentopyranosyl nucleoside compounds
US6617438B1 (en)1997-11-052003-09-09Sirna Therapeutics, Inc.Oligoribonucleotides with enzymatic activity
US6528640B1 (en)1997-11-052003-03-04Ribozyme Pharmaceuticals, IncorporatedSynthetic ribonucleic acids with RNAse activity
US6080543A (en)1997-12-082000-06-27E. & J. Gallo WineryDetection of fungal pathogens
US6582936B1 (en)1997-12-122003-06-24The Regents Of The University Of CaliforniaMethods for making nucleic acids
US6248519B1 (en)1998-03-112001-06-19E & J Gallo WineryDetection of fermentation-related microorganisms
US7045610B2 (en)1998-04-032006-05-16Epoch Biosciences, Inc.Modified oligonucleotides for mismatch discrimination
EP1077708A1 (en)1998-05-062001-02-28University Of Iowa Research FoundationMethods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO1999058118A2 (en)1998-05-141999-11-18Cpg Immunopharmaceuticals GmbhMETHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
US6242589B1 (en)1998-07-142001-06-05Isis Pharmaceuticals, Inc.Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en)1998-07-142005-03-15Isis Pharmaceuticals, Inc.Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
CA2333854A1 (en)1998-07-272000-02-10University Of Iowa Research FoundationStereoisomers of cpg oligonucleotides and related methods
US7049302B1 (en)1998-08-102006-05-23Antigenics Inc.Compositions of CPG and saponin adjuvants and uses thereof
JP3655550B2 (en)1998-08-142005-06-02独立行政法人科学技術振興機構 Nucleic acid capable of specifically binding to Ras target protein
WO2000023444A1 (en)1998-10-212000-04-27Abbott Laboratories5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en)1998-10-232006-02-07Sirna Therapeutics, Inc.Method for the chemical synthesis of oligonucleotides
US6423493B1 (en)1998-10-262002-07-23Board Of Regents The University Of Texas SystemCombinatorial selection of oligonucleotide aptamers
AU1742600A (en)1998-11-252000-06-13Isis Pharmaceuticals, Inc.Identification of disease predictive nucleic acids
US6451524B1 (en)1998-11-252002-09-17Isis Pharmaceuticals, Inc.Identification of disease predictive nucleic acids
EP1141335B1 (en)1998-12-212009-08-05Genencor International, Inc.Chemically modified enzymes with multiple charged variants
CA2359816C (en)1999-01-062010-08-03Genenews Inc.Method for the detection of gene transcripts in blood and uses thereof
US6265172B1 (en)1999-02-082001-07-24University Of KentuckyDiagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en)1999-03-162000-09-19Isis Pharmaceuticals, Inc.Phosphate and thiophosphate protecting groups
US6506594B1 (en)1999-03-192003-01-14Cornell Res Foundation IncDetection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en)1999-03-291999-05-26Goldsborough AndrewCleavage of nucleic acids from solid supports
JP3072345B1 (en)1999-03-312000-07-31農林水産省家畜衛生試験場長 Swine erysipelas recombinant subunit vaccine
DE19916417A1 (en)1999-04-012000-10-19Schering AgNew amyloid-specific aptamer, useful for diagnosis and/or treatment of e.g. Alzheimer's disease, is stabilized against nucleases
ATE375358T1 (en)1999-04-082007-10-15Antisoma Res Ltd ANTIPROLIFERATIVE ACTIVITY OF G-RICH OLIGONUCLEOTIDES AND METHOD FOR USING THEM TO BIND TO NUCLEOTIN
US6977245B2 (en)1999-04-122005-12-20The United States Of America As Represented By The Department Of Health And Human ServicesOligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en)1999-05-032001-10-09Qiagen GmbhGeneration and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en)1999-06-152003-12-02Isis Pharmaceuticals, Inc.Oligonucleotides conjugated to protein-binding drugs
US6066500A (en)1999-06-252000-05-23Isis Pharmaceuticals Inc.Antisense modulation of Beta catenin expression
US6271004B1 (en)1999-06-252001-08-07Display Systems Biotech A/SMethod for improved reverse transcription at high temperatures
US6569630B1 (en)1999-07-022003-05-27Conceptual Mindworks, Inc.Methods and compositions for aptamers against anthrax
US6414135B1 (en)1999-07-072002-07-02Isis Pharmaceuticals, Inc.C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en)2001-08-082003-05-15Crooke Rosanne M.Antisense modulation of cholesteryl ester transfer protein expression
DE19935756A1 (en)1999-07-272001-02-08Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
US6171795B1 (en)1999-07-292001-01-09Nexstar Pharmaceuticals, Inc.Nucleic acid ligands to CD40ligand
US6147200A (en)1999-08-192000-11-14Isis Pharmaceuticals, Inc.2'-O-acetamido modified monomers and oligomers
US7264932B2 (en)1999-09-242007-09-04Applera CorporationNuclease inhibitor cocktail
HUP0202639A2 (en)1999-09-252002-12-28Coley Pharm GmbhImmunostimulatory nucleic acids
US6949520B1 (en)1999-09-272005-09-27Coley Pharmaceutical Group, Inc.Methods related to immunostimulatory nucleic acid-induced interferon
MXPA02003059A (en)1999-09-272002-09-30Univ Iowa Res FoundMethods related to immunostimulatory nucleic acid induced interferon.
US20020082227A1 (en)1999-09-302002-06-27Scott HenryUse of oligonucleotides for inhibition of complement activation
IL148922A0 (en)1999-10-062002-09-12Quark Biotech IncMethod for enrichment of natural antisense messenger rna
JP3463098B2 (en)1999-10-082003-11-05独立行政法人産業技術総合研究所 Modulated aptamer and method for detecting target protein using the same
GB9924285D0 (en)1999-10-141999-12-15Avecia LtdProcess
US20010055761A1 (en)1999-10-292001-12-27Agilent TechnologiesSmall scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (en)1999-11-052003-01-31Centre Nat Rech Scient MEMBRANE PROTEINS CTL (CHOLINE TRANSPORTER LIKE) INVOLVED IN THE TRANSPORT OF CHOLINE
AU1656601A (en)1999-11-122001-06-12Isis Pharmaceuticals, Inc.Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en)1999-12-272001-11-27Technion Research And Development Foundation Ltd.Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
US7501091B2 (en)1999-12-302009-03-10Smiths Detection Inc.Sensors with improved properties
WO2001050349A1 (en)1999-12-302001-07-12Rutgers, The State University Of New JerseyElectronic document customization and transformation utilizing user feedback
US6649750B1 (en)2000-01-052003-11-18Isis Pharmaceuticals, Inc.Process for the preparation of oligonucleotide compounds
US6159697A (en)2000-01-192000-12-12Isis Pharmaceuticals, Inc.Antisense modulation of Smad7 expression
US7585847B2 (en)2000-02-032009-09-08Coley Pharmaceutical Group, Inc.Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2335389A1 (en)2000-03-012001-09-01Message Pharmaceuticals, Inc.Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
GB0004889D0 (en)2000-03-012000-04-19Avecia LtdSynthesis of oligonucleotides
JP2003528068A (en)2000-03-172003-09-24コリクサ コーポレイション New amphiphilic aldehydes and their use as adjuvants and immune effectors
DE10019756A1 (en)2000-04-202001-10-25Bayer Ag Process for the production of superabsorbent polymers from polyacrylonitriles
JP4219590B2 (en)2000-04-202009-02-04エフ.ホフマン−ラ ロシュ アーゲー Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
WO2001085751A1 (en)2000-05-092001-11-15Reliable Biopharmaceutical, Inc.Polymeric compounds useful as prodrugs
US6492171B2 (en)2000-05-162002-12-10Isis Pharmaceuticals, Inc.Antisense modulation of TERT expression
US6725412B1 (en)2000-08-152004-04-20Dolby Laboratories Licensing CorporationLow latency data encoder
US6809195B1 (en)2000-08-162004-10-26Isis Pharmaceuticals, Inc.Process for the preparation of oligonucleotides
US6559279B1 (en)2000-09-082003-05-06Isis Pharmaceuticals, Inc.Process for preparing peptide derivatized oligomeric compounds
EP1191097A1 (en)2000-09-212002-03-27Leids Universitair Medisch CentrumInduction of exon skipping in eukaryotic cells
US6376190B1 (en)2000-09-222002-04-23Somalogic, Inc.Modified SELEX processes without purified protein
EP2322648A1 (en)2000-09-262011-05-18Duke UniversityRNA aptamers and methods for identifying the same
GB0024752D0 (en)2000-10-102000-11-22Univ BelfastOxidative halogenation of aromatic compounds
US6933114B2 (en)2000-10-162005-08-23Gilead Sciences, Inc.Nucleic acid ligands to the prostate specific membrane antigen
BR0114786A (en)2000-10-182003-08-12Glaxosmithkline Biolog Sa Immunogenic composition, method of treatment of a patient suffering from, or susceptible to, a cancer, and, use of a combination of a saponin, an immunostimulating oligotide and a cancer antigen, and, method for the manufacture of a composition.
US6682889B1 (en)2000-11-082004-01-27Becton, Dickinson And CompanyAmplification and detection of organisms of the Chlamydiaceae family
JP2002165594A (en)2000-11-292002-06-11National Institute Of Advanced Industrial & Technology RNA molecules targeting hepatitis C virus IRES and NS3 protease
NL1016978C2 (en)2000-12-222002-06-25Robert Jan Colenbrander Device and method for packaging and preparing food and method for manufacturing such a device.
NZ526703A (en)2001-01-222004-12-24Merck & Co IncNucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8008459B2 (en)2001-01-252011-08-30Evolva SaConcatemers of differentially expressed multiple genes
ATE501251T1 (en)2001-01-252011-03-15Evolva Ltd CELL LIBRARY
JP4454934B2 (en)2001-01-262010-04-21コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Methods and means for producing efficient silencing constructs using recombinant cloning
US20050277133A1 (en)2001-05-182005-12-15Sirna Therapeutics, Inc.RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030207804A1 (en)2001-05-252003-11-06Muthiah ManoharanModified peptide nucleic acids
GB0113523D0 (en)2001-06-042001-07-25Torotrak Dev LtdAn Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en)2001-06-142003-04-10Isis Pharmaceuticals, Inc.Methods for preparing oligonucleotides having chiral phosphorothioate linkages
WO2003002065A2 (en)2001-06-292003-01-09Chiron CorporationHcv e1e2 vaccine compositions
JP2005504020A (en)2001-07-032005-02-10アイシス・ファーマシューティカルス・インコーポレーテッド Nuclease resistant chimeric oligonucleotide
US7205399B1 (en)2001-07-062007-04-17Sirna Therapeutics, Inc.Methods and reagents for oligonucleotide synthesis
US6440739B1 (en)2001-07-172002-08-27Isis Pharmaceuticals, Inc.Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en)2001-07-252008-09-16Isis Pharmaceuticals, Inc.Modulation of C-reactive protein expression
US7407943B2 (en)2001-08-012008-08-05Isis Pharmaceuticals, Inc.Antisense modulation of apolipoprotein B expression
US7888324B2 (en)2001-08-012011-02-15Genzyme CorporationAntisense modulation of apolipoprotein B expression
US6455308B1 (en)2001-08-012002-09-24Isis Pharmaceuticals, Inc.Antisense modulation of serum amyloid A4 expression
US7227014B2 (en)2001-08-072007-06-05Isis Pharmaceuticals, Inc.Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en)2001-08-072007-08-21Isis Pharmaceuticals, Inc.Modulation of apolipoprotein (a) expression
AU2002361468A1 (en)2001-08-142003-03-18The Government Of The United States Of America As Represented By The Secretary Of Health And Human SMethod for rapid generation of mature dendritic cells
US20030232978A1 (en)2001-08-242003-12-18Seeberger Peter H.Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en)2001-09-212006-05-23Academia SinicaMutant-type lipases and applications thereof
US6933288B2 (en)2002-02-042005-08-23Isis Pharmaceuticals, Inc.Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (en)2002-02-122009-10-21株式会社キラルジェン Method for producing highly stereoregular dinucleoside phosphorothioates
US20050096284A1 (en)2002-02-202005-05-05Sirna Therapeutics, Inc.RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2003106476A1 (en)2002-02-202003-12-24Sirna Therapeutics, IncNucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US8232383B2 (en)2002-02-202012-07-31Sirna Therapeutics, Inc.RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7288376B2 (en)2002-03-222007-10-30Council Of Scientific And Industrial ResearchMethod of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en)2002-11-232004-05-27Isis Pharmaceuticals Inc.Modulation of huntingtin interacting protein 2 expression
WO2003097662A1 (en)2002-05-152003-11-27Isis Pharmaceuticals, Inc.Antisense modulation of apolipoprotein b expression
US20040014108A1 (en)2002-05-242004-01-22Eldrup Anne B.Oligonucleotides having modified nucleoside units
WO2003099840A1 (en)2002-05-242003-12-04Isis Pharmaceuticals, Inc.Oligonucleotides having modified nucleoside units
WO2003102212A2 (en)2002-05-312003-12-11Regents Of The University Of MinnesotaIn vitro evaluation of nucleic acid ligands
US7507808B2 (en)2002-12-122009-03-24Isis Pharmaceuticals, Inc.Modulation of endothelial lipase expression
WO2003106477A1 (en)2002-06-012003-12-24Isis Pharmaceuticals, Inc.Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
AU2003242742B2 (en)2002-06-202009-04-30Cytos Biotechnology AgPackaged virus-like particles for use as adjuvants: method of preparation and use
WO2004003228A1 (en)2002-07-012004-01-08Unisearch LimitedGenotyping method
WO2004007718A2 (en)2002-07-102004-01-22MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Rna-interference by single-stranded rna molecules
US20040023905A1 (en)2002-07-312004-02-05Isis Pharmaceuticals Inc.Antisense modulation of LAR expression
EP1386972A1 (en)2002-08-012004-02-04Noxxon Pharma AGMethod and apparatus for designing a nucleic acid having a desired property
US20080274989A1 (en)2002-08-052008-11-06University Of Iowa Research FoundationRna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050255086A1 (en)2002-08-052005-11-17Davidson Beverly LNucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en)2002-08-052005-02-24Davidson Beverly L.RNA interference suppresion of neurodegenerative diseases and methods of use thereof
WO2004014933A1 (en)2002-08-072004-02-19University Of MassachusettsCompositions for rna interference and methods of use thereof
AR040996A1 (en)2002-08-192005-04-27Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
US7414116B2 (en)2002-08-232008-08-19Illumina Cambridge LimitedLabelled nucleotides
KR101360955B1 (en)2002-09-132014-02-10레플리코르 인코포레이티드non-sequence complementary antiviral oligonucleotides
US7030230B2 (en)2002-10-252006-04-18Isis Pharmaceuticals, Inc.Process of purifying phosphoramidites
MXPA05004588A (en)2002-10-292005-12-14Coley Pharmaceutical Group LtdUse of cpg oligonucleotides in the treatment of hepatitis c virus infection.
AU2003291755A1 (en)2002-11-052004-06-07Isis Pharmaceuticals, Inc.Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
CA2505090A1 (en)2002-11-052004-05-27Isis Pharmaceuticals, Inc.Conjugated oligomeric compounds and their use in gene modulation
AU2003291753B2 (en)2002-11-052010-07-08Isis Pharmaceuticals, Inc.Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044134A2 (en)2002-11-052004-05-27Isis Pharmaceuticals, Inc.Phosphorous-linked oligomeric compounds and their use in gene modulation
US7381527B2 (en)2002-11-062008-06-03Council Of Scientific And Industrial ResearchMethod of detection of SP-A2 gene variants
EP2336318B1 (en)2002-11-132013-04-24Genzyme CorporationAntisense modulation of apolipoprotein b expression
US7511131B2 (en)2002-11-132009-03-31Genzyme CorporationAntisense modulation of apolipoprotein B expression
EP2305812A3 (en)2002-11-142012-06-06Dharmacon, Inc.Fuctional and hyperfunctional sirna
AU2004220556B2 (en)2003-03-072009-05-07Alnylam Pharmaceuticals, Inc.Therapeutic compositions
GB0305422D0 (en)2003-03-102003-04-16Univ OpenDetection, monitoring and treatment of cancer
WO2004083432A1 (en)2003-03-212004-09-30Academisch Ziekenhuis LeidenModulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en)2003-03-242003-04-30Avecia LtdProcess and compounds
US7537767B2 (en)2003-03-262009-05-26Cytis Biotechnology AgMelan-A- carrier conjugates
ZA200507562B (en)2003-03-262006-11-29Cytos Biotechnology AgHIV-peptide-carrier-conjugates
ITRM20030149A1 (en)2003-04-022004-10-03Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
US7598227B2 (en)2003-04-162009-10-06Isis Pharmaceuticals Inc.Modulation of apolipoprotein C-III expression
EP2924119A1 (en)2003-04-212015-09-30Archemix LLCStabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7045306B2 (en)2003-04-282006-05-16The General Hospital CorporationMethod for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en)2003-05-072007-05-08E. I. Du Pont De Nemours And CompanyΔ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
CA2526893C (en)2003-05-142010-10-26Japan Science And Technology AgencyInhibition of the expression of huntingtin gene
EP2241572A3 (en)2003-06-032011-04-06Eli Lilly And CompanyModulation of survivin expression
MXPA05013922A (en)2003-06-202006-02-24Coley Pharm Group IncSmall molecule toll-like receptor (tlr) antagonists.
EP2530157B1 (en)2003-07-312016-09-28Regulus Therapeutics Inc.Oligomeric compounds and compositions for use in modulation of miRNAs
JP2005089441A (en)2003-08-082005-04-07Toudai Tlo Ltd Method for producing phosphorus atom-modified nucleotide analogues with high stereoregularity
JP2011088935A (en)2003-08-082011-05-06Chiralgen LtdOptically-active nucleoside 3'-phosphoroamidite for production of phosphorus atom modified nucleotide analog
US7825235B2 (en)2003-08-182010-11-02Isis Pharmaceuticals, Inc.Modulation of diacylglycerol acyltransferase 2 expression
ATE555118T1 (en)2003-08-282012-05-15Takeshi Imanishi NEW SYNTHETIC NUCLEIC ACIDS OF THE CROSS-LINKED N-O BOND TYPE
WO2005028494A1 (en)2003-09-022005-03-31Takeshi WadaProcess for producing 5'-phosphitylated monomer and h-phosphonate oligonucleotide derivative
WO2005023828A1 (en)2003-09-022005-03-17Takeshi WadaProcess for producing ribonucleotide or ribonucleotide derivative
WO2005023994A2 (en)2003-09-092005-03-17Geron CorporationModified oligonucleotides for telomerase inhibition
US20050074801A1 (en)2003-09-092005-04-07Monia Brett P.Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en)2003-09-092005-03-10Swayze Eric E.Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
CA2579638C (en)2003-09-122016-04-19University Of MassachusettsRna interference targeting non-disease causing single nucleotide polymorphisms within a gene encoding a gain-of-function mutant huntingtin protein
US8680063B2 (en)2003-09-122014-03-25University Of MassachusettsRNA interference for the treatment of gain-of-function disorders
GB0323968D0 (en)2003-10-132003-11-19Glaxosmithkline Biolog SaImmunogenic compositions
EA008741B1 (en)2003-10-302007-08-31Коли Фармасьютикал ГмбхC-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en)2003-10-312005-10-27Verdine Gregory LNucleic acid binding oligonucleotides
US7846436B2 (en)2003-11-282010-12-07Chemgenes CorporationOligonucleotides and related compounds
WO2005070859A1 (en)2004-01-272005-08-04Takeshi WadaFluorous supports and processes for production of oligonucleotide derivatives with the same
US20050176045A1 (en)2004-02-062005-08-11Dharmacon, Inc.SNP discriminatory siRNA
WO2005076744A2 (en)2004-02-182005-08-25Frutarom Ltd.Method for the preparation of peptide-oligonucleotide conjugates
JP3976742B2 (en)2004-02-272007-09-19江守商事株式会社 Immunostimulatory oligonucleotides that induce interferon alpha
WO2005085272A1 (en)2004-03-052005-09-15Takeshi WadaBoranophosphate monomer and process for producing oligonucleotide derivative therefrom
US20060193821A1 (en)2004-03-052006-08-31Diener John LAptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
JP4865544B2 (en)2004-03-252012-02-01株式会社キラルジェン Method for producing highly stereoregular ribonucleotide analogs and deoxyribonucleotide analogs
US20050244869A1 (en)2004-04-052005-11-03Brown-Driver Vickie LModulation of transthyretin expression
EP2540734B1 (en)2004-04-052016-03-30Alnylam Pharmaceuticals, Inc.Process and reagents for oligonucleotide synthesis and purification
EP1742959A2 (en)2004-04-262007-01-17Archemix CorporationNucleic acid ligands to immunoglobulin e and their use as atopic disease therapeutics
TWI350168B (en)2004-05-072011-10-11Incyte CorpAmido compounds and their use as pharmaceuticals
EP1753881A2 (en)2004-05-272007-02-21The Government of the United States of America as represented by The Secretary of the Department of Health and Human ServicesDifferential expression of molecules associated with acute stroke
US7759318B1 (en)2004-05-282010-07-20Isis Pharmaceuticals, Inc.Identification of novel pathways, genes and promoter motifs regulating adipogenesis
CA2568735A1 (en)2004-06-032005-12-22Isis Pharmaceuticals, Inc.Double strand compositions comprising differentially modified strands for use in gene modulation
ATE498685T1 (en)2004-06-282011-03-15Univ Western Australia ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHOD FOR THE USE THEREOF
EP2997980B1 (en)2004-08-102017-12-20Kastle Therapeutics, LLCMethods for modulating lipoprotein and cholesterol levels in humans
ES2386709T3 (en)2004-08-262012-08-27Nippon Shinyaku Co., Ltd. Phosphoramidite compound and method to produce an oligo-RNA
CA2579374A1 (en)2004-09-072006-03-30Archemix Corp.Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
WO2006029258A2 (en)2004-09-072006-03-16Archemix Corp.Aptamer medicinal chemistry
US7884086B2 (en)2004-09-082011-02-08Isis Pharmaceuticals, Inc.Conjugates for use in hepatocyte free uptake assays
WO2006031461A2 (en)2004-09-092006-03-23Isis Pharmaceuticals, Inc.Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
EP2397563A3 (en)2004-09-172012-07-18Isis Pharmaceuticals, Inc.Enhanced antisense oligonucleotides
JP4944034B2 (en)2004-10-132012-05-30アイシス ファーマシューティカルズ, インコーポレーテッド Antisense regulation of PTP1B expression
KR100721928B1 (en)2004-11-052007-05-28주식회사 바이오씨에스 Pharmaceutical composition for the treatment or prevention of skin diseases containing CJ oligodeoxynucleotide
EP1657307A1 (en)2004-11-162006-05-17Immunotech S.A.Oligonucleotides that induce the secretion of GM-CSF
US8003619B2 (en)2004-12-092011-08-23Alnylam Pharmaceuticals, Inc.Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
US9809824B2 (en)2004-12-132017-11-07The United States Of America, Represented By The Secretary, Department Of Health And Human ServicesCpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en)2004-12-172006-06-22Thiosense, Inc.Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20060183763A1 (en)2004-12-312006-08-17Pfizer IncNovel pyrrolidyl derivatives of heteroaromatic compounds
US20060166901A1 (en)2005-01-032006-07-27Yu Ruey JCompositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
KR100980898B1 (en)2005-01-282010-09-07권형주Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
EP1851314A2 (en)2005-02-242007-11-07Coley Pharmaceutical Group, Inc.Immunostimulatory oligonucleotides
JP2006248949A (en)2005-03-092006-09-21Univ Nagoya Nucleoside derivatives, nucleotide derivatives and methods for producing them
CN101189249B (en)2005-04-012013-04-17加利福尼亚大学董事会Phosphono-pent-2-en-1-yl nucleosides and analogs
ZA200709237B (en)2005-05-052009-04-29Antisense Pharma GmbhDosage of oligonucleotides
US7902352B2 (en)2005-05-062011-03-08Medtronic, Inc.Isolated nucleic acid duplex for reducing huntington gene expression
EP1885854B1 (en)2005-05-062012-10-17Medtronic, Inc.Methods and sequences to suppress primate huntington gene expression
CA2612401A1 (en)2005-06-152006-12-28The Ohio State University Research FoundationAptamers that bind to prion protein
US10242753B2 (en)2005-06-172019-03-26University Of WashingtonMethod for measuring strength of associations of multidimensional traits
PL2548560T3 (en)2005-06-232015-11-30Biogen Ma IncCompositions and methods for modulation of SMN2 splicing
EP2322657B1 (en)2005-06-282014-11-05Medtronic, Inc.Methods and sequences to preferentially suppress expression of mutated huntingtin gene.
US9133517B2 (en)2005-06-282015-09-15Medtronics, Inc.Methods and sequences to preferentially suppress expression of mutated huntingtin
WO2007005941A2 (en)2005-07-052007-01-11President And Fellows Of Harvard CollegeLiver targeted conjugates
JP4984634B2 (en)2005-07-212012-07-25ソニー株式会社 Physical information acquisition method and physical information acquisition device
CA2641599C (en)2005-07-282012-07-10Id-Fish Technology, Inc.Method for improving cell permeability to foreign particles
WO2007025049A2 (en)2005-08-262007-03-01Archemix Corp.Aptamers that bind thrombin with high affinity
JP5523705B2 (en)2005-08-292014-06-18レグルス・セラピューティクス・インコーポレイテッド Method of using to modulate MIR-122A
WO2007028065A2 (en)*2005-08-302007-03-08Isis Pharmaceuticals, Inc.Chimeric oligomeric compounds for modulation of splicing
WO2007035532A2 (en)2005-09-152007-03-29Duke UniversityFocused libraries, functional profiling, laser selex and deselex
US7700567B2 (en)2005-09-292010-04-20Supergen, Inc.Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en)2005-09-302007-04-05Midgley Timothy MMethod and apparatus for collecting user game play data and crediting users in a gaming environment
US8357665B2 (en)2005-10-122013-01-22Idera Pharmaceuticals, Inc.Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US9308252B2 (en)2005-10-272016-04-12Cook Biotech, Inc.Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CN101466834B (en)2005-10-282013-09-25东曹株式会社 Method for producing carotenoid-synthetic microorganisms and method for producing carotenoids
US7320965B2 (en)2005-10-282008-01-22Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of Huntingtin gene
KR20080075107A (en)2005-11-112008-08-14화이자 인코포레이티드 Combinations and Methods Using Immunomodulatory Oligodeoxynucleotides
WO2007064291A1 (en)2005-11-302007-06-07Jyoti ChattopadhyayaMethod and compounds for rna synthesis
WO2007064954A2 (en)2005-12-022007-06-07Isis Pharmaceuticals, Inc.Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en)*2005-12-132011-12-13Spring Bank Pharmaceuticals, Inc.Nucleotide and oligonucleotide prodrugs
RS20080281A (en)2005-12-212009-09-08Pfizer Products Inc.,Carbonylamino pyrolopyrazoles, potent kinase inhibitors
EP2161038B1 (en)2006-01-262013-12-25Isis Pharmaceuticals, Inc.Compositions and their uses directed to Huntingtin
ES2516815T3 (en)2006-01-272014-10-31Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids modified at position 6
CA2638847C (en)2006-02-142016-08-09Noxxon Pharma AgMcp-1 binding nucleic acids
US20080045473A1 (en)2006-02-152008-02-21Coley Pharmaceutical GmbhCompositions and methods for oligonucleotide formulations
EP4159220A1 (en)2006-03-082023-04-05Archemix LLCComplement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US8383660B2 (en)2006-03-102013-02-26Pfizer Inc.Dibenzyl amine compounds and derivatives
AU2007234451A1 (en)2006-03-312007-10-11Atom Acquisition, LlcReagents useful for synthesizing rhodamine-labeled oligonucleotides
EP2010679A2 (en)2006-04-062009-01-07Ibis Biosciences, Inc.Compositions for the use in identification of fungi
WO2007122103A1 (en)2006-04-202007-11-01F. Hoffmann-La Roche AgDiazepan derivatives modulators of chemokine receptors
EP2020449B1 (en)2006-04-242012-09-26Sigma Alimentos, S.A. De C.V.Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
US20100008937A1 (en)2006-04-252010-01-14Immune Disease Institute, Inc.Targeted delivery to leukocytes using non-protein carriers
GB0608838D0 (en)2006-05-042006-06-14Novartis AgOrganic compounds
ES2471978T3 (en)2006-05-052014-06-27Isis Pharmaceuticals, Inc. Compounds and procedures to modulate ApoB expression
WO2007131232A2 (en)2006-05-052007-11-15Isis Pharmaceuticals, Inc.Compositions and their uses directed to ptpr alpha
US20090012120A1 (en)2006-05-102009-01-08Board Of Trustees Of Michigan State UniversitySynthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
US7666854B2 (en)2006-05-112010-02-23Isis Pharmaceuticals, Inc.Bis-modified bicyclic nucleic acid analogs
CN101490074B (en)2006-05-112013-06-26Isis制药公司 5'-Modified Bicyclic Nucleic Acid Analogs
JP2009538325A (en)2006-05-262009-11-05リガド・バイオサイエンシーズ・インコーポレーテツド Administration of REG1 anticoagulant system
PL2034015T3 (en)2006-05-312012-11-30Toray IndustriesImmunostimulatory oligonucleotide and pharmaceutical application thereof
US8097596B2 (en)2006-06-302012-01-17Lakewood-Amedex, Inc.Compositions and methods for the treatment of muscle wasting
EP2046993A4 (en)2006-07-072010-11-17Univ Massachusetts RNA INTERFERENCE COMPOSITIONS AND METHOD FOR TREATING MORBUS HUNTINGTON
WO2008008884A2 (en)2006-07-122008-01-17Cornell Research Foundation, Inc.Inhibition of beta-amyloid peptide aggregation
EP2046964B1 (en)2006-07-122018-07-04The Regents of The University of CaliforniaTransducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
CN103555725B (en)2006-07-182017-05-24诺松制药股份公司Sdf-i binding nucleic acids
US7666888B2 (en)2006-07-202010-02-23Amgen Inc.Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
CN100503824C (en)2006-07-202009-06-24武汉大学Micromolecule nucleotide DNA aptamer for resisting mycobacterium tuberculosis infection and preparation method thereof
WO2008017081A1 (en)2006-08-042008-02-07Isis Pharmaceuticals, Inc.Compositions and methods for the modulation of jnk proteins
AT504194B1 (en)2006-09-072008-07-15Oesterr Rotes Kreuz BACTERIA DETECTION
EP1897562A1 (en)2006-09-082008-03-12Bayer Schering Pharma AktiengesellschaftAptamers labelled with Gallium-68
US8138330B2 (en)2006-09-112012-03-20Sigma-Aldrich Co. LlcProcess for the synthesis of oligonucleotides
PT2078080E (en)*2006-09-272015-09-18Coley Pharm GmbhCpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
ATE540118T1 (en)2006-10-182012-01-15Isis Pharmaceuticals Inc ANTISENSE COMPOUNDS
WO2008051763A1 (en)2006-10-232008-05-02Irm LlcCathepsin proteases inhibitors
KR20090058584A (en)2006-10-262009-06-09콜리 파마슈티칼 게엠베하 Oligoribonucleotides and Uses thereof
FR2908414B1 (en)2006-11-132012-01-20Centre Nat Rech Scient IMMOBILIZATION OF MEMBRANE PROTEINS ON A SUPPORT THROUGH AN AMPHIPHILE MOLECULE
MX2009005252A (en)2006-11-172009-05-28Abbott LabAminopyrrolidines as chemokine receptor antagonists.
US8093222B2 (en)2006-11-272012-01-10Isis Pharmaceuticals, Inc.Methods for treating hypercholesterolemia
KR20090103894A (en)2006-11-272009-10-01아이시스 파마수티컬즈 인코포레이티드Methods for treating hypercholesterolemia
KR100861108B1 (en)2006-11-282008-09-30(주) 벡스코아Nuclease-Resistant RNA Aptamer Inhibiting Replication of Hepatitis C Virus Replicon
JP2010512421A (en)2006-12-122010-04-22イデラ ファーマシューティカルズ インコーポレイテッド Synthetic agonist of TLR9
UY30892A1 (en)2007-02-072008-09-02Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
WO2008101157A1 (en)2007-02-152008-08-21Isis Pharmaceuticals, Inc.5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2682082A1 (en)2007-03-242008-10-02Genzyme CorporationAdministering antisense oligonucleotides complementary to human apolipoprotein b
JP2010525826A (en)2007-05-032010-07-29ロゼッタ インファーマティックス エルエルシー Composition comprising a MIR34 therapeutic for treating cancer
WO2008141308A2 (en)2007-05-112008-11-20Adynxx, Inc.Gene expression and pain
CN101678098A (en)*2007-05-172010-03-24科勒制药集团公司Class a oligonucleotides with immunostimulatory potency
CA2688008A1 (en)2007-05-242008-11-27Kyorin Pharmaceutical Co., Ltd.Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
GB0710186D0 (en)2007-05-292007-07-04Texas Instr DenmarkPWM loop with minimum allasing error property
ES2388590T3 (en)2007-05-302012-10-16Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids with N-substituted aminomethylene bridge.
AU2008258599B2 (en)2007-06-052013-06-13Nsab, Filial Af Neurosearch Sweden Ab, SverigeDisubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154401A2 (en)2007-06-082008-12-18Isis Pharmaceuticals, Inc.Carbocyclic bicyclic nucleic acid analogs
US20100298280A1 (en)2007-06-132010-11-25Petra Kioschis-SchneiderCompounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds
DE602007005629D1 (en)2007-06-182010-05-12Commissariat Energie Atomique Reversible siRNA silencing of a mutated and endogenous HD wild-type gene and its use in the treatment of Huntington's disease
EP2176280B2 (en)2007-07-052015-06-24Isis Pharmaceuticals, Inc.6-disubstituted bicyclic nucleic acid analogs
JP5737937B2 (en)2007-07-092015-06-17イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. Stabilized immunomodulatory RNA (SIMRA) compounds
EP2185723A4 (en)2007-07-312011-01-12Univ Saskatchewan GENETIC MODIFICATIONS OF THE PMCH HORMONE GENE AFFECTING THE CHARACTERISTICS OF LIVESTOCK CARCASSES
EP2185700A4 (en)2007-08-022010-11-24Texas A & M Univ Sys ANTISENSE MICRO RNA AND USES THEREOF
EP2179061B1 (en)2007-08-152012-10-03Idera Pharmaceuticals, Inc.Toll like receptor modulators
KR101660989B1 (en)2007-10-012016-09-28아이오니스 파마수티컬즈, 인코포레이티드Antisense modulation of fibroblast growth factor receptor 4 expression
KR100886139B1 (en)2007-11-132009-02-27주식회사 삼천리제약 Method for preparing oligonucleotide
AR069869A1 (en)2007-12-212010-02-24Exelixis Inc BENZOFIDE DERIVATIVES [3,2-D] PROTEINQUINASE INHIBITING PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER.
TWI340765B (en)2007-12-262011-04-21Ind Tech Res InstOligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
CN101911676A (en)2008-01-152010-12-08联发科技股份有限公司Multimedia processing device and method for playing a plurality of video signals and a plurality of audio signals and multimedia playing system
WO2009089659A1 (en)2008-01-182009-07-23Shanghai Targetdrug Co., Ltd.Pyrollidine-based compounds
EP2240768A1 (en)2008-02-042010-10-20Galapagos N.V.Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (en)2008-02-122009-08-27Tokyo Institute Of Technology Oligonucleotide derivatives
WO2009117589A1 (en)2008-03-212009-09-24Isis Pharmaceuticals, Inc.Oligomeric compounds comprising tricyclic nucleosides and methods for their use
US20110130440A1 (en)2008-03-262011-06-02Alnylam Pharmaceuticals, Inc.Non-natural ribonucleotides, and methods of use thereof
CN102123716B (en)2008-04-032013-09-18春堤公司 Compounds and methods for treating viral infections
DK2285819T3 (en)2008-04-042013-12-02Isis Pharmaceuticals Inc OLIGOMER COMPOUNDS INCLUDING NEUTRAL BONDED, TERMINAL BICYCLIC NUCLEOSIDES
CA2726866A1 (en)2008-05-092009-11-12The University Of British ColumbiaMethods and compositions for the treatment of huntington's disease
US8679750B2 (en)2008-05-092014-03-25The University Of British ColumbiaMethods and compositions for the treatment of Huntington'S disease
US8541388B2 (en)2008-05-222013-09-24Isis Pharmaceuticals, Inc.Methods for modulating expression of RBP4
EP2294181A4 (en)2008-05-222013-04-24Isis Pharmaceuticals Inc MODULATION OF SMRT EXPRESSION
WO2009143391A2 (en)2008-05-222009-11-26Isis Pharmaceuticals, IncMethods for modulation expression of creb
WO2009148605A2 (en)2008-06-042009-12-10Isis Pharmaceuticals, Inc.Methods for treating hypercholesterolemia
CA2728559A1 (en)2008-07-032010-01-07Exelixis Inc.Cdk modulators
WO2010039543A2 (en)2008-09-232010-04-08Traversa Therapeutics, Inc.Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
DK2361256T3 (en)2008-09-242013-07-01Isis Pharmaceuticals Inc Cyclohexenyl-nucleic acid analogues
WO2010036698A1 (en)2008-09-242010-04-01Isis Pharmaceuticals, Inc.Substituted alpha-l-bicyclic nucleosides
US20110257251A1 (en)2008-10-072011-10-20Presidents And Fellows Of Harvard CollegeTelomerase inhibitors and methods of use thereof
KR101672563B1 (en)2008-10-222016-11-03쿠아크 파마수티칼스 인코퍼레이티드Methods for treating eye disorders
JP5763539B2 (en)2008-10-242015-08-12アイシス ファーマシューティカルズ, インコーポレーテッド 5 'and 2' bis-substituted nucleosides and oligomeric compounds produced therefrom
CN102282155B (en)2008-12-022017-06-09日本波涛生命科学公司The synthetic method of the nucleic acid of phosphorus atoms modification
CA2747999A1 (en)2008-12-232010-07-01Girindus America, Inc.Sulfurizing reagents and their use for oligonucleotides synthesis
WO2010080953A1 (en)2009-01-082010-07-15Isis Pharmaceuticals, Inc.Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
US20120264806A1 (en)2009-02-062012-10-18Bennett C FrankOligomeric compounds and excipients
EP2396409A2 (en)2009-02-102011-12-21Idera Pharmaceuticals, Inc.Synthetic rna-based agonists of tlr7
EP2669290A1 (en)2009-03-022013-12-04Alnylam Pharmaceuticals Inc.Nucleic Acid Chemical Modifications
EP2408796B1 (en)2009-03-162020-04-22Ionis Pharmaceuticals, Inc.Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
WO2010118263A1 (en)2009-04-082010-10-14University Of MassachusettsSingle-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
CA2759098A1 (en)2009-04-142010-10-21Smith Holdings, LlcMethods and compositions for the treatment of medical conditions involving cellular programming
US9260493B2 (en)2009-05-072016-02-16The Regents Of The University Of CaliforniaTransducible delivery of nucleic acids using modified dsRNA binding domains
CA2801178A1 (en)2009-06-012010-12-09The Regents Of The University Of CaliforniaNucleic acid delivery compositions and methods of use thereof
TWI549688B (en)2009-06-052016-09-21美國疾病傳染研究機構 Synthetic grape pyranosyl lipid adjuvant
EP3305302B1 (en)2009-06-172018-09-19Biogen MA Inc.Compositions and methods for modulation of smn2 splicing in a subject
WO2011005764A1 (en)2009-07-062011-01-13Ada Technologies, Inc.Electrochemical device and method for long-term measurement of hypohalites
KR101885383B1 (en)*2009-07-062018-08-03웨이브 라이프 사이언시스 리미티드Novel nucleic acid prodrugs and methods of use thereof
WO2011005860A2 (en)2009-07-072011-01-13Alnylam Pharmaceuticals, Inc.5' phosphate mimics
EP2451974A2 (en)2009-07-082012-05-16Idera Pharmaceuticals, Inc.Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011015573A1 (en)2009-08-032011-02-10Galapagos NvMolecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en)2009-08-032011-02-10Galapagos NvMolecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011017521A2 (en)2009-08-062011-02-10Isis Pharmaceuticals, Inc.Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en)2009-08-102015-01-06Daljit Singh DhanoaDeuterium-enriched alkyl sulfonamides and uses thereof
MX340397B (en)2009-09-112016-07-07Ionis Pharmaceuticals IncModulation of huntingtin expression.
US8470987B2 (en)2009-09-162013-06-25Chiralgen, Ltd.Protective group for synthesis of RNA and derivative
WO2011038288A1 (en)2009-09-252011-03-31Isis Pharmaceuticals, Inc.Modulation of ttc39 expression to increase hdl
JP5629324B2 (en)2009-10-152014-11-19ファイザー・インク Pyrrolo [2,3-D] pyrimidine compounds
WO2011075560A1 (en)2009-12-172011-06-23Merck Sharp & Dohme Corp.Aminopyrimidines as syk inhibitors
KR101433114B1 (en)2009-12-282014-08-22아키라 랩스 프라이빗 리미티드Diagnostic gel composition, method for making a diagnostic gel composition
US8653047B2 (en)2010-01-082014-02-18Isis Pharmaceuticals, Inc.Modulation of angiopoietin-like 3 expression
US8750507B2 (en)2010-01-252014-06-10Cisco Technology, Inc.Dynamic group creation for managed key servers
CA2789038A1 (en)2010-02-082011-08-11Isis Pharmaceuticals, Inc.Selective reduction of allelic variants
ES2733708T3 (en)2010-02-082019-12-02Ionis Pharmaceuticals Inc Selective reduction of allelic variants
BR112012018904A2 (en)2010-02-102020-09-01Glaxosmithkline Llc compound, vaccine adjuvant, immunogenic, vaccine and pharmaceutical compositions, and use of a compound "
US8859755B2 (en)2010-03-052014-10-14Chiralgen, Ltd.Method for preparing ribonucleoside phosphorothioate
WO2011127175A1 (en)2010-04-062011-10-13Isis Pharmaceuticals, Inc.Modulation of cd130 (gp130) expression
CA2795750A1 (en)2010-04-072011-10-13Isis Pharmaceuticals, Inc.Modulation of cetp expression
WO2011133871A2 (en)2010-04-222011-10-27Alnylam Pharmaceuticals, Inc.5'-end derivatives
WO2011139699A2 (en)2010-04-282011-11-10Isis Pharmaceuticals, Inc.5' modified nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (en)2010-04-282016-09-07Ionis Pharmaceuticals, Inc.Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)2010-04-292011-11-10Isis Pharmaceuticals, Inc.Lipid formulated single stranded rna
GB201008902D0 (en)2010-05-272010-07-14Imp Innovations LtdMembrane enhanced polymer sythesis
KR20130100278A (en)2010-08-312013-09-10머크 샤프 앤드 돔 코포레이션Novel single chemical entities and methods for delivery of oligonucleotides
WO2012039448A1 (en)2010-09-242012-03-29株式会社キラルジェンAsymmetric auxiliary group
JP5996431B2 (en)2010-09-302016-09-21Lsipファンド運営合同会社 Dominant mutant gene expression inhibitor
KR101381048B1 (en)2010-10-202014-04-14씨제이제일제당 (주) Process for producing L-cysteine or derivatives thereof from O-phosphoseline producing strains and O-phosphoseline produced therefrom
EP3766975A1 (en)2010-10-292021-01-20Sirna Therapeutics, Inc.Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012058693A2 (en)*2010-10-292012-05-03Alnylam Pharmaceuticals, Inc.Compositions and methods for inhibition of pcsk9 genes
EP3260540A1 (en)2010-11-122017-12-27The General Hospital CorporationPolycomb-associated non-coding rnas
JP6093924B2 (en)2010-11-302017-03-15株式会社Wave Life Sciences Japan 2'-O-modified RNA
US10017764B2 (en)2011-02-082018-07-10Ionis Pharmaceuticals, Inc.Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CA2827380C (en)2011-02-122020-08-25University Of Iowa Research FoundationTherapeutic nucleic acids
US9353371B2 (en)2011-05-022016-05-31Ionis Pharmaceuticals, Inc.Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (en)2011-05-242013-07-05Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
US9605019B2 (en)2011-07-192017-03-28Wave Life Sciences Ltd.Methods for the synthesis of functionalized nucleic acids
US20150051389A1 (en)2011-08-112015-02-19Isis Pharmaceuticals, Inc.Selective antisense compounds and uses thereof
US20140080896A1 (en)2011-08-302014-03-20The Regents Of The University Of CaliforniaIdentification of small molecules that facilitate therapeutic exon skipping
JP2015502365A (en)2011-12-122015-01-22オンコイミューニン,インコーポレイティド In vivo delivery of oligonucleotides
CN102675386B (en)2011-12-242014-07-02河南科技大学Method for separating and purifying gentiamarin
WO2013134558A1 (en)2012-03-072013-09-12The Texas A & M University SystemCancer treatment targeting non-coding rna overexpression
KR20130114435A (en)2012-04-092013-10-17삼성전자주식회사Biomolecule detection apparatus including a plurality of electrode
US9284344B2 (en)2012-05-302016-03-15Hokkaido System Science Co., Ltd.Oligonucleotide synthesis method using highly dispersible liquid-phase support
AU2013288048A1 (en)2012-07-132015-01-22Wave Life Sciences Ltd.Asymmetric auxiliary group
SG10201912895PA (en)2012-07-132020-02-27Wave Life Sciences LtdChiral control
KR101835401B1 (en)2012-07-132018-03-08신 니뽄 바이오메디칼 라보라토리즈, 엘티디.Chiral nucleic acid adjuvant
EP2879718B1 (en)2012-08-062023-06-07Alnylam Pharmaceuticals, Inc.Processes for the preparation of carbohydrate conjugated rna agents
KR102237882B1 (en)2012-08-152021-04-07아이오니스 파마수티컬즈, 인코포레이티드Method of preparing oligomeric compounds using modified capping protocols
EP4086347A3 (en)2012-10-122023-01-11Ionis Pharmaceuticals, Inc.Selective antisense compounds and uses thereof
JP2016503300A (en)2012-11-152016-02-04ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S Anti-ApoB antisense complex compound
RU2015120645A (en)2012-11-262017-01-10Рош Инновейшен Сентер Копенгаген А/С COMPOSITIONS AND METHODS OF MODULATION OF EXPRESSION OF RECEPTOR OF FACTOR OF GROWTH FIBROBLAST 3 TYPE (FGFR3)
WO2014118267A1 (en)2013-01-302014-08-07Santaris Pharma A/SLna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en)2013-01-302014-08-07Santaris Pharma A/SAntimir-122 oligonucleotide carbohydrate conjugates
ES2817050T3 (en)2013-02-042021-04-06Ionis Pharmaceuticals Inc Selective antisense compounds and uses thereof
BR112015027321A8 (en)2013-05-012018-01-02Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
WO2014189142A1 (en)2013-05-242014-11-27味の素株式会社Morpholino oligonucleotide manufacturing method
KR20160013110A (en)2013-05-242016-02-03로슈 이노베이션 센터 코펜하겐 에이/에스Oligonucleotide modulators of b-cell cll/lymphoma 11a(bcl11a) and uses thereof
AU2014300981B2 (en)2013-06-272017-08-10Roche Innovation Center Copenhagen A/SAntisense oligomers and conjugates targeting PCSK9
TWI702046B (en)2013-07-192020-08-21美商Ionis製藥公司Compositions for modulating tau expression
CN105579582A (en)2013-07-252016-05-11埃克西奎雷股份有限公司 Spherical nucleic acid-based constructs as immunostimulants for prophylactic and therapeutic use
BR112016007255A2 (en)2013-10-032017-09-12Moderna Therapeutics Inc polynucleotides encoding low density lipoprotein receptor
EP3052627B1 (en)2013-10-042018-08-22Novartis AGNovel formats for organic compounds for use in rna interference
JP2016537341A (en)2013-11-112016-12-01サンガモ バイオサイエンシーズ, インコーポレイテッド Methods and compositions for treating Huntington's disease
KR20160083876A (en)2013-11-142016-07-12로슈 이노베이션 센터 코펜하겐 에이/에스Apob antisense conjugate compounds
EP2918275B1 (en)2013-12-132016-05-18Moderna Therapeutics, Inc.Alternative nucleic acid molecules and uses thereof
EP3095459A4 (en)2014-01-152017-08-23Shin Nippon Biomedical Laboratories, Ltd.Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (en)2014-01-152017-03-23株式会社新日本科学 Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
WO2015108047A1 (en)2014-01-152015-07-23株式会社新日本科学Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JP6382344B2 (en)2014-01-162018-08-29ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. Chiral design
EP3647318B1 (en)2014-04-282021-06-30Ionis Pharmaceuticals, Inc.Linkage modified oligomeric compounds
ES2844593T3 (en)2014-05-012021-07-22Ionis Pharmaceuticals Inc Compositions and procedures to modulate the expression of angiopoietin type 3
BR112016025849A2 (en)2014-05-082017-10-17Chdi Foundation Inc methods and compositions for the treatment of huntington's disease
EP3146051B8 (en)2014-05-202019-11-27University of Iowa Research FoundationHuntington's disease therapeutic compounds
US20160017327A1 (en)2014-07-112016-01-21The Johns Hopkins UniversityPhosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
US20170204152A1 (en)2014-07-162017-07-20Moderna Therapeutics, Inc.Chimeric polynucleotides
EP2982758A1 (en)2014-08-042016-02-10Centre Hospitalier Universitaire Vaudois (CHUV)Genome editing for the treatment of huntington's disease
IL316808A (en)2014-08-202025-01-01Alnylam Pharmaceuticals IncModified double-stranded rna agents and uses thereof
WO2016037191A1 (en)2014-09-052016-03-10Health Research, Inc.Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
US20180112217A1 (en)2014-11-192018-04-26Roche Innovation Center Copenhagen A/SStereospecific Phosphorothioate LNA
WO2016096938A1 (en)2014-12-162016-06-23Roche Innovation Center Copenhagen A/SChiral toxicity screening method
HUE043842T2 (en)2014-12-242019-09-30Uniqure Ip BvRnai induced huntingtin gene suppression
US9688707B2 (en)2014-12-302017-06-27Ionis Pharmaceuticals, Inc.Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
EP3254104B1 (en)2015-02-042021-08-25Bristol-Myers Squibb CompanyMethods of selecting therapeutic molecules
US20180023081A1 (en)2015-02-042018-01-25Bristol-Myers Squibb CompanyLna oligonucleotides with alternating flanks
HK1247641A1 (en)2015-02-102018-09-28Genzyme CorporationVARIANT RNAi
AU2016219263B2 (en)2015-02-132022-12-01Alnylam Pharmaceuticals, Inc.Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
EP3262174A4 (en)2015-02-232018-10-17Ionis Pharmaceuticals, Inc.Compounds and methods for increasing antisense activity
EP3265098B1 (en)2015-03-032025-03-26Ionis Pharmaceuticals, Inc.Compositions for modulating mecp2 expression
WO2016154096A1 (en)2015-03-202016-09-29Ionis Pharmaceuticals, Inc.Modulation of smggds expression
CA2980337A1 (en)2015-04-032016-10-06University Of MassachusettsOligonucleotide compounds for targeting huntingtin mrna
WO2016164896A2 (en)2015-04-102016-10-13Ionis Pharmaceuticals, Inc.Modulation of smn expression
US10407678B2 (en)2015-04-162019-09-10Ionis Pharmaceuticals, Inc.Compositions for modulating expression of C9ORF72 antisense transcript
WO2016209862A1 (en)2015-06-232016-12-29Alnylam Pharmaceuticals, Inc.Glucokinase (gck) irna compositions and methods of use thereof
EP3313989B1 (en)2015-06-292024-12-25Ionis Pharmaceuticals, Inc.Modified crispr rna and modified single crispr rna and uses thereof
KR102640776B1 (en)2015-07-102024-02-23아이오니스 파마수티컬즈, 인코포레이티드 Diacylglycerol acyltransferase 2 (DGAT2) regulator
WO2017011286A1 (en)2015-07-102017-01-19Alnylam Pharmaceuticals, Inc.Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
DK3324980T3 (en)2015-07-172022-02-14Alnylam Pharmaceuticals Inc MULTI-TARGETED SIMPLICITY CONJUGATES
MA43072A (en)2015-07-222018-05-30Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
US20180216114A1 (en)2015-07-272018-08-02Alnylam Pharmaceuticals, Inc.Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
DK3329002T3 (en)2015-07-312021-01-11Alnylam Pharmaceuticals Inc TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS FOR USING IT FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES
DK3341479T3 (en)2015-08-242020-02-24Roche Innovation Ct Copenhagen As LNA-G Process
IL293355B2 (en)2015-08-252024-07-01Alnylam Pharmaceuticals IncMethods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
JP7028764B2 (en)2015-09-022022-03-02アルナイラム ファーマシューティカルズ, インコーポレイテッド Programmed cell death 1 Ligand 1 (PD-L1) iRNA composition and its usage
WO2017055423A1 (en)2015-10-022017-04-06Roche Innovation Center Copenhagen A/SOligonucleotide conjugation process
AU2016334232B2 (en)2015-10-092022-05-26Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
EP3183347A4 (en)2015-10-172018-04-18Lifesplice Pharma LLCSplice modulating oligonucleotides and methods of use thereof
WO2017068087A1 (en)2015-10-222017-04-27Roche Innovation Center Copenhagen A/SOligonucleotide detection method
WO2017067970A1 (en)2015-10-222017-04-27Roche Innovation Center Copenhagen A/SIn vitro toxicity screening assay
KR102185465B1 (en)2015-11-122020-12-03에프. 호프만-라 로슈 아게 Oligonucleotides for inducing paternal UBE3A expression
EP3430019A4 (en)2016-03-132019-10-30Wave Life Sciences Ltd. COMPOSITIONS AND METHODS FOR SYNTHESIZING PHOSPHORAMIDITY AND OLIGONUCLEOTIDES
CN114085836B (en)2016-03-142024-01-26豪夫迈·罗氏有限公司Oligonucleotides for reducing PD-L1 expression
US11267843B2 (en)2016-03-182022-03-08Roche Innovation Center Copenhagen A/SStereodefining L-monomers
CN109153697A (en)2016-04-142019-01-04豪夫迈·罗氏有限公司Mono- GalNAc compound of trityl-and application thereof
MA45270A (en)2016-05-042017-11-09Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
MA45290A (en)2016-05-042019-03-13Wave Life Sciences Ltd PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
US11261209B2 (en)2016-05-122022-03-01Roche Innovation Center Copenhagen A/SEnhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
US10752891B2 (en)2016-05-132020-08-25Roche Molecular Systems, Inc.Protein-based sample collection matrices and devices
MA45188A (en)2016-06-032019-04-10Wave Life Sciences Ltd OLIGONUCLEOTIDES, ASSOCIATED COMPOSITIONS AND METHODS
WO2018022473A1 (en)2016-07-252018-02-01Wave Life Sciences Ltd.Phasing
CN110088113A (en)2016-11-232019-08-02波涛生命科学有限公司Composition and method for phosphoramidite and oligonucleotide synthesis
US11597927B2 (en)2017-06-022023-03-07Wave Life Sciences Ltd.Oligonucleotide compositions and methods of use thereof
CN111164091B (en)2017-06-022025-01-07波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
JP2020522510A (en)2017-06-022020-07-30ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. Oligonucleotide composition and method of using the same
CN111051281A (en)2017-06-212020-04-21波涛生命科学有限公司Compounds, compositions and methods for synthesis
WO2019002237A1 (en)2017-06-282019-01-03Roche Innovation Center Copenhagen A/SMultiple coupling & oxidation method
US20200362337A1 (en)2017-08-082020-11-19Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
KR20250123934A (en)2017-09-182025-08-18웨이브 라이프 사이언시스 리미티드Technologies for oligonucleotide preparation
WO2019075357A1 (en)2017-10-122019-04-18Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
WO2019126651A1 (en)2017-12-212019-06-27Alnylam Pharmaceuticals, Inc.Chirally-enriched double-stranded rna agents
IL277889B2 (en)2018-04-122025-01-01Wave Life Sciences LtdOligonucleotide compositions and methods of use thereof
WO2019217784A1 (en)2018-05-112019-11-14Wave Life Sciences Ltd.Oligonucleotide compositions and methods of use thereof
WO2020118246A1 (en)2018-12-062020-06-11Wave Life Sciences Ltd.Oligonucleotide compositions and methods thereof
CN113423385A (en)2019-02-012021-09-21波涛生命科学有限公司Oligonucleotide compositions and methods thereof
FR3093595B1 (en)2019-03-072022-03-11Thales Sa CALIBRATION SYSTEM FROM THE GROUND OF A PAYLOAD OF A SATELLITE
SG11202110045PA (en)2019-03-202021-10-28Wave Life Sciences LtdTechnologies useful for oligonucleotide preparation
US20220307019A1 (en)2019-03-252022-09-29National University Corporation Tokyo Medical And Dental UniversityDouble-stranded nucleic acid complex and use thereof
EP3958872A4 (en)2019-04-252024-07-03Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
CA3137741A1 (en)2019-04-252020-10-29Wave Life Sciences Ltd.Oligonucleotide compositions and methods of use thereof
JP2022532169A (en)2019-05-092022-07-13ウェイブ ライフ サイエンシズ リミテッド Oligonucleotide composition and its usage
US20230220384A1 (en)2019-10-062023-07-13Prashant MonianOligonucleotide compositions and methods of use thereof
MX2022004102A (en)2019-10-062022-04-26Wave Life Sciences LtdOligonucleotide compositions and methods of use thereof.
US20230295619A1 (en)2020-03-012023-09-21Abbie Madeline MaguireOligonucleotide compositions and methods thereof
US20230203087A1 (en)2020-05-222023-06-29Pachamuthu KandasamyOligonucleotide compositions and methods thereof

Also Published As

Publication numberPublication date
AU2025201455A1 (en)2025-03-20
ES2940887T3 (en)2023-05-12
AU2020244546B2 (en)2022-09-22
KR20210016078A (en)2021-02-10
IL236621B (en)2019-12-31
KR20150036642A (en)2015-04-07
US20210130821A1 (en)2021-05-06
AU2018205183A1 (en)2018-08-02
CL2015000092A1 (en)2015-08-07
RU2015104762A3 (en)2018-08-31
WO2014012081A3 (en)2014-03-06
WO2014012081A2 (en)2014-01-16
SG11201500232UA (en)2015-04-29
PL2872147T3 (en)2023-09-25
JP7004637B2 (en)2022-02-04
JP2015528002A (en)2015-09-24
US20240229026A1 (en)2024-07-11
JP2022050518A (en)2022-03-30
JP6453212B2 (en)2019-01-16
EP4219516A2 (en)2023-08-02
KR102213609B1 (en)2021-02-08
KR102450907B1 (en)2022-10-04
US10590413B2 (en)2020-03-17
JP2019069971A (en)2019-05-09
CA2878945A1 (en)2014-01-16
US20150211006A1 (en)2015-07-30
US11643657B2 (en)2023-05-09
US20170275621A1 (en)2017-09-28
EP2872147A4 (en)2016-01-20
AU2022291426A1 (en)2023-02-02
CN112007045A (en)2020-12-01
CN104661664A (en)2015-05-27
CN104661664B (en)2020-07-03
JP2025066783A (en)2025-04-23
EP4219516A3 (en)2024-01-10
JP7625544B2 (en)2025-02-03
KR102712879B1 (en)2024-10-04
US9982257B2 (en)2018-05-29
KR20240148947A (en)2024-10-11
MX2015000577A (en)2015-08-14
AU2013289880B2 (en)2018-08-02
AU2018205183B2 (en)2020-07-02
KR20220139425A (en)2022-10-14
IL236621A0 (en)2015-02-26
DK2872147T3 (en)2023-02-20
EP2872147B1 (en)2022-12-21
AU2013289880A1 (en)2015-02-05
EP2872147A2 (en)2015-05-20
AU2020244546A1 (en)2020-10-29
HK1210595A1 (en)2016-04-29
SG10201700283WA (en)2017-03-30
RU2015104762A (en)2018-08-31

Similar Documents

PublicationPublication DateTitle
IL236621A0 (en)Chiral control
GB2500583B (en)Interference control
IL235019A0 (en)Substituted pyrrolidine-2-carboxamides
EP2834259A4 (en)Modified polynucleotides
SG11201404344XA (en)Substituted pyrrolidine-2-carboxamides
GB201221069D0 (en)Control method
GB2522151B (en)Component temperature control
GB2507584B (en)Control circuitry
EP2811284A4 (en)Control unit
ZA201500837B (en)Rendering time control
GB201215667D0 (en)Control assembly
EP2934541A4 (en)Substituted noribogaine
IL235613A0 (en)Printhead control
PL2802488T3 (en)Wiper control
PL2636959T3 (en)Heater control
GB201300597D0 (en)Clearance control
PL2674683T3 (en)Heating control
GB2518990B (en)Controls
GB2505396B (en)Flow control
GB201210472D0 (en)Obtaining control words
GB201119829D0 (en)Showwer control
HK40097122A (en)Chiral control
GB201218924D0 (en)Clearance control
AU342207S (en)Jewelley setting
GB201203956D0 (en)Controls

[8]ページ先頭

©2009-2025 Movatter.jp